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The Extent and Nature Of Chromosomal
Rearrangements in B Lymphocytes

Isaac Andrew Klein, Ph.D.
The Rockefeller University 2012

Chromosomal rearrangements, including translocations, require formation and
joining of DNA double strand breaks (DSBs). These events disrupt the integrity of
the genome and are frequently involved in producing leukemias, lymphomas and
sarcomas. Mature B cell lymphomas are unique among tumors in that they
frequently carry clonal recurrent translocations. This may be the result of
Activation Induced Cytidine Deaminase (AID) expression, which introduces a
heretofore uncharacterized array of rearrangements. Despite the importance of
these events, current understanding of their genesis is limited.

To examine the origins of chromosomal rearrangements we developed
Translocation

Capture

Sequencing

(TC-Seq),

a

method

to

document

chromosomal rearrangements to a fixed DSB genome-wide, in primary cells. We
examined over 180,000 rearrangements obtained from 400 million activated B
lymphocytes to two loci, IgH and c-myc. Our data and analysis reveal that

proximity between DSBs, transcriptional activity and chromosome territories are
key determinants of genome rearrangement. Specifically, rearrangements tend to
occur in cis and to transcribed genes. We also find that AID induces
rearrangement in specific hotspots. Hotspots are predominantly genic,
transcribed, and are found as translocation partners in mature B cell lymphoma.

Amplius est amplius
(More is More)
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CHAPTER 1:
Introduction

Chromosomal Translocations

Chromosomal rearrangements are a variation in the normal structure of the
genome. They may be the result of translocation, deletion, inversion or insertion;
thereby uniting disparate parts of the genome with or without the deletion of
intervening sequence. Rearrangements can be physiological, as in the antibody
diversification reactions of B lymphocytes. Or they may pathological, as in the
Philadelphia chromosome observed in chronic myelogenous leukemia.

The chromosomal translocation is a genomic rearrangement caused by the
exchange of arms between two non-heterologous chromosomes. They are
commonly found in leukemias, lymphomas and sarcomas and are key
pathogenic events in cancer. Translocations can confer a survival or proliferative
advantage upon an incipient cancer cell by: juxtaposing proto-oncogenes to
constitutively active promoters, deleting tumor suppressors, or producing
chimeric oncogenes (Nussenzweig and Nussenzweig, 2010).
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Translocations are the most common class of cytogenetic abnormality in
hematologic malignancies (Kuppers, 2005). These events are often clonal,
indicative of their role in triggering or maintaining transformation and progression,
and are highly stereotyped within tumor classes. Within the hematologic
malignancies, there are classical examples of the functional and diagnostic
implications of translocations. The Philadelphia chromosome, a translocation
between chromosome 9 and 22 (t(9;22)(q34.1;q11.2)), is observed in chronic
myelogenous leukemia. This rearrangement juxtaposes the 5’ region of the BCR
gene to the 3’ region of the Abl gene generating a constitutively active tyrosine
kinase, BCR-Abl, which drives tumor growth (Sawyers, 1993). The discovery of
this fusion oncogene led to the successful development of diagnostic tests to
identify the tumor, and the development of a drug to halt tumor growth in patients
(Druker et al., 2001). Another example is Burkitt’s lymphoma, a mature B cell
cancer associated with t(8;14)(q24;q32). This rearrangement places the
immunoglobulin heavy chain regulatory elements next to the c-myc protooncogene. c-myc is thereby over expressed, which leads to malignant
transformation (Gostissa et al., 2009).

Translocagenesis requires that three primary criteria be fulfilled. First, paired
DNA breaks must occur on different chromosomes (Richardson and Jasin, 2000).
DNA damage may occur by exogenous modes such as ionizing radiation and
chemical exposure, or by endogenous modes such as replication errors, cellular
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metabolism and genetically programmed damage. Second, translocation partners
must be in proximity to one another in the nucleus, a function of the threedimensional architecture of the genome (Roix et al., 2003). Recent studies have
demonstrated that chromatin features, transcriptional activity, and hormone
exposure may influence genomic architecture generally, and the proximity of
specific translocation partners (Lieberman-Aiden et al., 2009; Mani et al., 2009).
Finally, DSBs on heterologous chromosomes must be joined in trans (as
opposed to faithful repair of the DSB). This is largely a function of the DNA repair
pathway responsible for break resolution; both pathway choice and abnormalities
in repair pathways may influence the genesis of chromosomal translocations.

3

Origins of DNA Double Strand Breaks

The genome is under constant threat of DNA damage from both exogenous and
endogenous sources. Damage may be the result of environmental insults,
cellular metabolism, genomic features and development. DNA damage, if
repaired improperly, may result in genomic rearrangement. Nearly every DNA
damaging agent or event has been shown to lead to chromosomal
rearrangement, and in many cases, with implications for oncogensis or other
human diseases.

Oxidative stress. In a cell, reactive oxygen species come from multiple sources
including UV light, aerobic metabolism, and enzymatic activity. Oxidative stress
occurs when there is a greater abundance of these reactive oxygen species
(ROS) than the cell’s capacity to neutralize them. If such an overabundance
occurs, free oxidants may react with DNA to generate adducts and numerous
downstream products including DNA breaks (Marnett, 2000). Oxide radical
production and the resulting DNA damage has been shown to cause genomic
rearrangements. For example, the absence of a peroxiredoxin (an antioxidant
enzyme) in yeast causes increased frequency of chromosomal rearrangements
(Huang and Kolodner, 2005). And, in diseases characterized by DNA repair
defects such as xeroderma pigmentosum and ataxia telangiectasia, ROS are
hypothesized to play a role in the observed genomic instability (Barzilai et al.,
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2002).

Ionizing radiation and chemical compounds. Both Ionizing radiation (IR) and
certain chemicals may react directly with DNA, altering its chemical structure and
resulting in damage. Ionizing radiation, defined as electromagnetic waves with
sufficient energy to remove electrons from target atoms, causes double stranded
DNA breaks (DSBs) at the rate of ~35 per Gy (Rogakou et al., 1998). IR-induced
breaks are known precursors to rearrangement. For example, children exposed
to radiation from the Chernobyl disaster suffer from high rates of papillary thyroid
carcinoma, which bear rearrangements of the RET proto-oncogene (Fugazzola et
al., 1995). RET rearrangements are detected in human thyroid tissue upon
exposure to ionizing radiation, and their incidence in tissue culture is directly
proportional to the dosage of radiation (Caudill et al., 2005).

Clinically, ionizing radiation is employed in radiotherapy, where a focused beam
is used to introduce DSBs in cancer cells, thereby inducing cell death. Ionizing
radiation is also an essential tool for studying DNA damage in the laboratory
setting. It has been used extensively to characterize the nature of the DNA
damage response and the retinue of proteins that bind sites of damage.
However, its usefulness is limited by our inability to apply irradiation in a spatially
controlled manner.
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Certain

chemicals

may

also

cause

DNA

damage.

Clinically,

many

chemotherapeutic agents act in this way, thereby selectively targeting quickly
growing cells that undergo rapid replication. For example, alkylating agents such
as cisplatin form covalent bonds with DNA bases, generating crosslinks that elicit
the DNA damage response, induce apoptosis, and interfere with replication
(Lawley and Phillips, 1996). Topoisomerase inhibitors on the other hand, directly
cause DSBs. The enzyme topoisomerase II generates then religates DSBs to
relieve tension caused by supercoils and tangles. Rapidly dividing cancer cells
are particularly dependent on this enzyme to facilitate replication and
transcription. The drug etoposide binds to topoisomerase II preventing the
religation of broken ends, thereby generating DSBs. These DSBs may serve as
substrates for translocation (Libura et al., 2005). For example, TOP2 inhibition
has been shown to generate breaks in the mixed lineage leukemia (MLL) cluster
region. Patients treated for acute lymphoblastic leukemia (ALL) with TOP2
inhibitors may thereafter suffer rearrangement of the MLL gene, which can lead
to therapy-related acute myeloid leukemias (Blanco et al., 2001).

Replicative stress. During DNA replication, stalling of replication forks may be the
result of sequence features such as repeat rich sequences, loci with complex
secondary structure, nucleotide deficiency, assorted forms of DNA damage or
collisions between replication and transcription machinery (Mani and Chinnaiyan,
2010). Normally, fork stalling leads to ssDNA generation that affects downstream
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fork repair and checkpoint activation (Allen et al., 2011). An unrepaired
replication fork however, may give rise to unusual DNA structures and collapse
into a double strand break, a phenomenon that may also occur upon a fork
encounter with a single strand nick (Ammazzalorso et al., 2010).

DNA breaks originating from replication fork collapse may serve as intermediates
in the formation of complex chromosomal rearrangements, structures that involve
reorganization of sequence from breakpoints on three or more chromosomes. It
has been proposed that broken 3’ ends from collapsed replication forks anneal to
extra-chromosomal single stranded DNA based on homology. Annealed ssDNAs
then polymerize, and in a series of template changes followed by the continuation
of replication, complex chromosomal rearrangements are formed (Hastings et al.,
2009). These structures have been observed in female patients suffering from
multiple recurrent abortions and in male patients with hypospermatogenesis or
spermatogenic arrest (Kim et al., 2011).

Common fragile sites. In 1984 Glover and collegues notes that when aphidicolin
(an inhibitor of DNA polymerase) is added to a cell culture, chromosomes
develop non-random gaps on metaphase spreads. These gaps became more
frequent with folic acid deprivation and appeared to match gaps found by
previous studies of spontaneous chromosomal damage (albeit at a much lower
frequency). The breaks were present in 12 of 12 cultures tested so they were
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termed common fragile sites (Glover et al., 1984), and they were attributed to
conditions of partial replicative stress. About 80 of these sites are currently
known, however, they are coarsely mapped; generally they are only localized to
chromosome bands. A sequence feature is very likely to underlie this
phenomenon, but the exact cause of their emergence is unknown. Common
fragile sites examined to date are mainly AT-rich sequences (Zlotorynski et al.,
2003). And, it has been hypothesized that fragile sites appear in late replicating
regions of the genome (Dillon et al., 2010). It is also possible that fragile sites
represent long regions of ssDNA that tend to form secondary structures, leading
to replication fork stalling and collapse (Dillon et al., 2010).

DSBs resulting from common fragile sites have been implicated in the formation
of chromosomal rearrangements. In a study that examined all known cancerassociated recurrent translocations, 52% occurred within known fragile site
positions (Burrow et al., 2009). In one specific case, the most frequently
expressed fragile site in the human genome, FRA3B, is located within the tumor
suppressor gene FHIT (Huebner and Croce, 2001). Deletions of FHIT are
associated with cancer of the breast, lung, cervix, and esophagus.

Transcriptional stress. Transcription induces a multitude of changes on the DNA.
It may change DNA conformation, strandedness, position and the local milieu of
proteins. Additionally, it may interact with existing processes on the DNA such as
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replication or DNA repair and with lesions such as altered bases. As a
consequence of these changes and interactions, transcription can compromise
genomic stability in the form of increased mutation and recombination rates.

The phenomenon of transcription-associated mutation was first described 40
years ago by studies in prokaryotes. In E. coli, alkylating agent induced mutation
of the β-galactosidase gene is stimulated by transcription (Brock, 1971). And, in
the presence of acridine (a mutagen) lac null mutations are reverted more
frequently in the presence of transcription (Herman and Dworkin, 1971). The
persistence of ssDNA at the transcription bubble may account for this instability;
many mutagenic reactions are more efficient on ssDNA than dsDNA (Aguilera,
2002). For example, in bacteria, spontaneous deamination of cytosine is 140-fold
more efficient on ssDNA than on dsDNA (Frederico et al., 1990). And, in E. Coli
mutation of LacI and human hprt is more prominent on the non-transcribed strand
(which is open ssDNA) as compared to the transcribed strand (which is in
complex with RNA and multiple proteins) (Fix and Glickman, 1987). Finally, with
an RNA polymerase mutant characterized as having a slow elongation rate
transcription-associated mutation is higher than with a wild type polymerase. This
may suggest that mutations rates depend on the length of time that DNA is held
in an open, single stranded conformation (Beletskii et al., 2000).

In addition to increasing mutation rates, transcription appears to boost
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recombination rates as well. Evidence for transcriptionally active recombinogenic
DNA in eukaryotes was first described in the context of recombination hotspots,
high levels of recombination were observed between nearby genes in the hotspot
HOT1 (in the ribosomal RNA genes) (Keil and Roeder, 1984). Later work showed
that transcription by RNA polymerase I was responsible and required for the
recombination (Voelkel-Meiman et al., 1987). Eventually, this phenomenon was
shown in regions transcribed by RNA Polymerase II; transcription enhanced
recombination 15 fold between directly repeated sequences of GAL10 in S.
cerevisiae (Thomas and Rothstein, 1989).

In 1990, Nickoloff and colleagues provided the first evidence for transcription
associated recombination in mammalian cells. They found that transcription
between heteroallelic neomycin genes on extrachromosomal plasmids was
significantly stimulated in the presence of transcription (Nickoloff and Reynolds,
1990); the same effect was shown with intra-chromosomal recombination of
integrated substrates (Nickoloff, 1992). Interestingly, transcription does not
appear to increase the frequency of DSB induced recombination and does not
change the spectrum of recombination events from a DSB. For example, when
an I-SceI break is introduced in a direct repeat of a neo gene, transcription does
not change the frequency of recombination between repeats, the repair pathway
used or the size of deletions at the break (Allen et al., 2003). This suggests that
transcription may be enhancing the generation of recombinogenic lesions, not
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enhancing the recombinogenicity of existing lesions. Of note, transcription
enhances the use of a donor sequence in DSB-induced recombination
(Schildkraut et al., 2006).

There are several theories to explain the phenomenon of transcription-associated
recombination. First, transcription may expose ssDNA that is more prone to
damage and thereby, recombination. Given the propensity of transcriptionassociated mutations to occur on the exposed single strand of the transcription
bubble, one might reason that this is a likely mechanism for recombination as
well (Aguilera, 2002). In cells treated with a carcinogen 4-nitroquiniline-N-oxide
transcription appears to synergize with DNA damage to drive recombination
frequencies distantly above background levels (>4000 fold) (Garcia-Rubio et al.,
2003). This suggests that transcription indeed increases the availability of DNA,
and perhaps ssDNA, for damage and recombination. However, to our knowledge
it has never been directly shown that recombination is more likely to occur to
regions of ssDNA.

Another non-mutually exclusive possibility is that transcription associated
recombination might be caused by replication fork/transcription bubble collisions.
Replication and transcription can take place on the same strand at the same
time; these processes might obstruct one another, resulting in stalled and
collapsed replication forks. These events may result in rearrangement. For
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example, when replication and transcription are initiated in opposite directions on
an extrachromosomal substrate in E coli, up to 12 percent of the isolated plasmid
sustains deletions (Vilette et al., 1996). In this situation, the replication fork has
been shown to stall for several minutes, which may result in collapse and ensuing
damage (Liu and Alberts, 1995). Supporting this model of transcription
associated recombination Gottipati and colleagues have shown that the
phenomenon tends to occur in S phase, suggesting that it is dependent on
replication (Gottipati et al., 2008)

Genetically programmed DSBs. During T and B lymphocyte development,
antigen receptor diversification occurs by virtue of specific DNA breaks and
recombination events. The enzymes responsible for generating these breaks
may contribute to genomic instability via promiscuous joining of physiological
DSBs and generation of off-target DSBs. V(D)J recombination, catalyzed by a
site-specific nuclease RAG1/2, generates antigen receptor variable region
diversity by combining gene segments in myriad permutations. RAG1/2
introduces nicks at recombination signal sequences that convert to double strand
breaks by transesterification (Roth, 2003). Unresolved ends from RAG breaks in
the immunoglobulin loci may partner with other DSBs to generate oncogenic
rearrangements, as in the bcl-2/IgH translocation observed in follicular lymphoma
(Jager et al., 2000). Additionally, RAGs can function as a transposase, which
may be a means for rearrangement production (Brandt and Roth, 2004). They
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may also introduce breaks in various non-antigen receptor loci including those
bearing non-B DNA structures or cryptic recombination signal sequences
(Raghavan et al., 2001; Raghavan et al., 2004). However, the extent of these
non-Ig breaks and their locations remain unknown.

Mature B cells suffer genomic insult from two additional diversification reactions
catalyzed

by

Activation

Induced

Cytidine

Deaminase

(AID).

Somatic

hypermutation introduces non-templated mutations in the immunoglobulin genes
during B cell activation in the germinal center. Class switch recombination
changes the immunoglobulin constant region in a deletional recombination
reaction catalyzed by double strand breaks in switch regions. In addition to acting
on physiological targets, AID may generate DSBs throughout the genome
(Nussenzweig

and

Nussenzweig,

2010).

V(D)J

recombination,

somatic

hypermutation and class switch recombination will be discussed in greater detail
in later sections.
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DNA Repair Pathways in Translocagenesis

Maintaining genomic integrity is key to cellular survival and proliferation. As such,
multiple DNA repair pathways have evolved to recognize and repair DNA
damage. Depending on the repair pathway, DNA breaks may be rejoined
faithfully or may generate rearrangements. Additionally, defects in a pathway
may result in unfaithful break repair. There are three major DNA repair pathways
thought to repair DSBs; homologous recombination (HR), non-homologous end
joining (NHEJ) and alternative non-homologous end joining (Alt-NHEJ).

Homologous recombination. HR is a primary pathway in the S and G2 phase of
the cell cycle, during which time it repairs DSBs by using a sister chromatid
template. In this pathway DNA ends must first be resected by exonucleases,
leaving a 3’ single stranded end. Exposed ssDNA is then bound by Replication
Protein A (RPA) and Rad51 to form a nucleoprotein filament. This process also
requires the MRN complex, BRCA1 and BRCA2. The filament carries out a
homology search eventually forming a displacement loop on a homologous
sequence. The invading strand then copies sequence from the template strand.
Repair can result in crossover or non-crossover repair products (Moynahan and
Jasin, 2010).
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Homologous recombination plays an important role in maintaining genomic
integrity; if the pathway is fractured cells suffer an increase in genomic instability
(Sonoda et al., 1998). Specifically, in the absence of HR cells exhibit an increase
of double strand breaks at fragile sites (Schwartz et al., 2005). Loss of certain HR
components may also result in the accumulation of genomic abnormalities. For
example, the loss of BRCA1 or BRCA2 leads to chromosomal radial structures,
which are fusions between different chromosomes (Patel et al., 1998). Radial
structures may break during mitosis resulting in breakage-bridge fusion cycles
that give rise to translocations. Finally, loss of BRCA1 function is observed in
inherited breast cancer, indicating the importance of this pathway in preventing
oncogensis (Ford et al., 1994).

Non-homologous end joining. NHEJ is the so-called “error prone” repair pathway,
which may occur throughout the cell cycle, but predominantly in G1 (Takata et
al., 1998). Breaks are repaired by simply reattaching the ends, rather than
copying from a homologous strand, so bases may be lost or mutated at the
junctions. Briefly, in this pathway Ku70-Ku80 heterodimers bind the broken ends,
which recruits DNA dependent protein kinase catalytic subunit (DNA-PKcs) to
form a synaptic complex. Thereafter, the LigaseIV-Xrcc4 complex religates the
broken ends (Lieber, 2008). Ataxia-telangiectasia mutated protein (ATM), a
serine/threonine kinase, is responsible for phosphorylating numerous DNA repair
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effectors, cell cycle checkpoint proteins and for amplifying the DNA damage
signal (Derheimer and Kastan, 2010).

The classical NHEJ factors are required for faithful DSB repair, V(D)J
recombination, and for efficient class switch recombination (Manis et al., 2002;
Nussenzweig et al., 1996; Zhu et al., 1996). In the absence of NHEJ factors,
there

is

a

dramatic

increase

in

persistent

DSBs

and

chromosomal

rearrangements (Difilippantonio et al., 2000). So, NHEJ suppresses aberrant
rejoining events, including translocations, while encouraging appropriate intrachromosomal repair. Consistent with this idea, translocations generated by
RAGs, AID and homing endonucleases do not require the NHEJ factors Ku70,
Ku80, DNA-PKcs or XRCC4, rather, translocation formation is increased in their
absence (Boboila et al., 2010a; Callen et al., 2009; Wang et al., 2009; Weinstock
et al., 2007). An intact NHEJ pathway is also required to suppress oncogensis.
For example, mice lacking p53 and Ku80 develop early onset pro-B cell
lymphomas

characterized

by

recurrent

chromosomal

translocations

(Difilippantonio et al., 2000).

Alternative non-homologous end joining. Alt-NHEJ is a poorly defined pathway,
but is likely of great importance in generating chromosomal rearrangements. AltNHEJ is primarily characterized by presence of microhomology (~>4 nucleotides)
and deletion at the repaired junction, beyond what is normally observed at
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junctions generated by the NHEJ pathway (Lieber, 2008). The presence of
microhomology at junctions was first described in 1986 (Roth and Wilson, 1986).
Since then, the existence of a specific pathway has been demonstrated (Yan et
al., 2007). While Alt-NHEJ is most robust in cells with a disabled classical NHEJ,
it appears to perform repair even in the presence of an intact NHEJ pathway
(Corneo et al., 2007). Several proteins have been implicated in Alt-NHEJ,
including Mre11 and CtIP, which are notable for their involvement in end
resection and ssDNA generation (Bennardo et al., 2008; Deriano et al., 2009;
Lee-Theilen et al., 2011).

Alt-NHEJ appears to play a role in chromosomal translocation. In the absence of
NHEJ factors Ku70 and Ligase4 or Xrcc4 and Ligase4, breaks are more likely to
partner in translocations, and the junctions of those events bear microhomologies
– indicating the role of alt-NHEJ in their formation (Boboila et al., 2010a; Simsek
and Jasin, 2010). Additional evidence can be found in a mouse model of RAGmediated lymphomagenesis. Deriano and colleagues generated mice that lack
p53 and express a truncated form of RAG2, coreRAG2. coreRAG2 releases DNA
ends after cleavage, allowing them to be accessed and repaired by the alt-NHEJ
pathway (Corneo et al., 2007). These mice develop lymphomas bearing
chromosomal rearrangements showing: the role of alt-NHEJ in generating
genomic

abnormalities,

the

importance
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of

those

abnormalities

in

lymphomagenesis,

and

the

role

classical

NHEJ

rearrangements and oncogensis (Deriano et al., 2011).
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in

suppressing

Spatial Proximity in Translocagenesis

To form a rearrangement DSBs must be in proximity to one another. The
proximity of two loci may be impacted by several factors including the
constitutional architecture of the genome, transcription, chromatin accessibility
and signaling pathways. While the 3D structure and dynamics of the genome are
still emerging there appear to be certain principles dictating its form and, they
may exert effects on the genomic rearrangement landscape.

1st order genomic architecture: chromosome territories. An organization of
interphase chromosomes was first proposed in the 19th century, and Theodore
Boveri coined the term chromosome territory in 1909. In Boveri’s studies of the
horse roundworm blastomere he noted that chromosome ends protruding from
the nucleus maintained their position as the cell transitioned from prophase,
during which individual chromosomes are visible, to interphase. He concluded
that the chromosome territory is stably maintained during the cell cycle (Cremer
and Cremer, 2010). Subsequent light microscopy studies supported these
assertions (Stack et al., 1977), but in electron micrographs of the nucleus
chromosome territorial integrity appeared to dissolve, so the idea was largely
forsaken.
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Recent studies have resurrected the concept of chromosome territories. Direct
visual evidence was first obtained by in situ hybridization on total human DNA in
cell hybrids containing only one human chromosome on a background of
Chinese hamster ovary chromosomes (Manuelidis, 1985). Indeed, individual
human chromosomes could be delineated during interphase. The advent of 3D
fluorescent in situ hybridization and specific probes has allowed higher resolution
studies of chromosome territories. These have confirmed their existence. For
example, differential coloring of all 24 chromosomes in human fibroblasts
followed by serial sections of laser confocal microscopy images showed excellent
separation of distinct chromosome territories (Bolzer et al., 2005).

High throughput DNA sequencing has provided yet another tool for examining
nuclear structure. In 2009 Lieberman-Aiden and colleagues developed Hi-C (High
throughput chromosome conformation capture). In Hi-C, cells are cross-linked (to
preserve long-rage chromatin interactions) then DNA is digested with restriction
endonucleases. Ends are filled in with biotinylated nucleotides and the resulting
blunt fragments are ligated under dilute conditions that promote ligation between
cross-linked DNA fragments. The result is a pool in which fragments of DNA
residing in close nuclear proximity are ligated and marked with a biotin. A high
throughput paired-end library is assembled from biotinylated fragments,
sequenced, and a catalog of nuclear interactions is developed. This study
showed that intra-chromosomal contacts are more likely than trans-chromosomal
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contacts, indicating the presence of chromosome territories (Figure 1.1)
(Lieberman-Aiden et al., 2009).

Adapted from Lieberman-Aiden et al., 2009

Figure 1.1. Hi-C data indicates the presence of chromosome territories. The
probability of intra-chromosomal contact between DNA fragments (solid line)
exceeds the probability of trans-chromosomal contact (dotted lines) at any
distance between fragments mapping to the same chromosome (LiebermanAiden et al., 2009).

The existence of chromosome territories may impact the rearrangement
landscape across the genome. A 2009 report from Mahowald and colleagues
demonstrated a system for cloning breakpoints from aberrantly resolved RAG
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DSBs generated during V(D)J recombination in Atm-/- Abelson transformed pre-B
cells. They showed that 60% of rearrangements occur to points on the same
chromosome as the recombination substrate, rather than to trans-chromosomal
targets. And, of these intra-chromosomal targets 87% were within 200kb of the
recombination substrate. This study suggests that intra-chromosomal joining may
be preferred to trans-chromosomal joining, however, they examined a small
number of rearrangements limiting the certainty of the results (Mahowald et al.,
2009). Firm proof that chromosome territories influence the landscape of
rearrangements is still lacking, and whether this phenomenon occurs locally or
over the entire chromosome is unknown. For this issue to be addressed, a much
greater quantity of data is required in primary cells.

2nd order genomic architecture: functional compartments. In the interphase
nucleus perhaps the most obvious forms of nuclear organization are the
heterochromatic and euchromatic compartments. These compartments, which
are easily visible by light microscopy, represent transcriptionally active open
chromatin and transcriptionally inactive closed chromatin. In eukaryotes,
heterochromatin tends toward the nuclear envelope while euchromatin lies
centrally in the nucleus, and this organization relates to gene activation. For
example, immunoglobulin loci only active in pro-B cells are positioned at the
nuclear periphery in pro-T cells and hematopoietic precursors, but are centrally
located in pro-B cell nuclei (Kosak et al., 2002). And, active and inactive alleles of
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a mono-allelicly expressed astrocyte specific protein, GFAP, occupy different
subnuclear compartments and radial positions in the nucleus depending on their
functional status (Takizawa et al., 2008). These observations suggest that
transcriptional activity is a mediator of genome organization.

Hi-C revealed transcription- and chromatin conformation-dependent levels of
genome organization. First, gene rich chromosomes interact with one another.
This suggests that in regard to chromosome relationships, genes influence the
nuclear position. Hi-C data analysis also revealed two general spatial
compartments within the nucleus. The presence of genes, hypersensitivity to
DNAseI and high transcription levels (as measured by mRNA levels) accounted
for the differences between these two compartments. Thus, the genome consists
of two neighborhoods; active and inactive loci (Lieberman-Aiden et al., 2009).
Whether this level of organization impacts the genomic rearrangement profile or
the joining behavior of specific breaks remains unclear. Some bias for genic
rearrangements has been demonstrated in deep sequencing experiments on
human tumors (as will be discussed at the end of this section). However,
rearrangements in tumors may be selected or a function of some cancer specific
joining aberration, so it is difficult to draw general conclusions about the nature of
rearrangements from these studies.
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Proximity of specific partners. The importance of proximity in rearrangement
propensity is demonstrated by studies of specific oncogenic rearrangement
partners. Average proximity of loci correlates with their rearrangement frequency,
indicating that proximity is a determinant of translocation. For example, Burkitt’s
lymphoma is characterized by translocations involving c-myc. Clinically, c-myc
fusion to the immunoglobulin heavy chain (IgH) is common, while fusion to the
immunoglobulin light chain kappa (IgK) is infrequent (Roix et al., 2003). In
experiments using FISH in a cytogenetically normal B-lymphoblast cell line, Roix
and colleagues demonstrated that c-myc is in closer proximity to IgH than IgK
(Roix et al., 2003). In the same study, similar relationships were described for
other translocation partners. This suggests that proximity might dictate
rearrangement propensity.

Many rearrangements are cell-type specific. The proximity of specific
translocation partners is also cell-type specific and related to the occurrence of
rearrangement. For example, he BCR-Abl fusion of chronic myelogenous
leukemia occurs in an early hematopoietic stem cell while the promyelocytic
leukemia protein (PML) – retinoic acid receptor alpha (RAR-alpha) fusion of
acute promyelocytic leukemia occurs in committed hematopoietic precursors
(Mani and Chinnaiyan, 2010). In a population of cells containing early
hematopoietic stem cells, BCR and Abl are in close proximity while PML and
RAR-alpha are not (Neves et al., 1999). This is further evidence that proximity is
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a determinant of rearrangement and suggests that the cell-type specificity of
rearrangements may be a function of partner locus proximity.

Signaling pathways within an individual cell type may also influence the proximity
of partner loci, and thereby effect rearrangement generation. This phenomenon
can be observed in the ETS gene rearrangements that fuel prostate cancer.
These rearrangements yield fusions of the 5’ UTR of an androgen-regulated
gene with ETS family genes (ERG, ETV1, ETV4, ETV5); of these, TMPRSS2ERG is the most common (Helgeson et al., 2008; Lin et al., 2009). Treating
human prostate cancer cells with dihydrotestosterone (DHT) induces proximity
between these partners by a myosin and actin dependent mechanism (Mani et
al., 2009). When subjected to irradiation, these cells then form TMPRSS2-ERG
rearrangements. The authors of this study conclude that signaling pathways can
effect the position of certain rearrangement partners. This phenomenon may play
an important role in the formation of recurrent chromosomal aberrations.
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Next Generation Analysis of Rearrangements in Tumors.

Next generation sequencing technologies have facilitated the in depth
examination of cancer genomes. These technologies enable the generation of
transcriptome, methylome, genome and epigenetic maps. Of particular relevance
to this study, cancer genome sequences have provided a high-resolution view of
some cytogenetic abnormalities in human cancer. While the events sequenced
from tumors are highly selected, and may be formed by aberrant cancer-cell
specific mechanisms, the landscape of rearrangements in cancer may reveal
some principles of chromosomal rearrangement.

Rearrangements in tumors may be examined by transcriptome sequencing of
cDNA. This limits the number of reads required to achieve complete coverage,
and thereby limits the cost of analysis; however, only a small fraction of the
genome can be viewed. In a study of the breast cancer cell line HCC1954 this
technique was successfully employed to discover novel rearrangements. By
mining the sequencing data for chimeric reads (those mapping to two disparate
loci), Zhao et al discovered 7 cDNAs representing 6 transchromosomal events
and 1 intrachromosomal event, all of which could be confirmed by FISH, genomic
DNA PCR or cDNA PCR (Zhao et al., 2009). Some events appeared to have
oncogenic significance. For example, they found truncating translocation of
MRE11A, a protein involved in DNA repair. And, a translocation of NSD1 (a gene
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fusion partner in acute myeloid leukemia) was found to an intergenic sequence
on chromosome 8 (Zhao et al., 2009). This approach can successfully discover
some

cytogenetic

abnormalities.

Unfortunately,

the

limited

number

of

rearrangements obtained does not provide sufficient power to make any
conclusions about the global rearrangement profile of this line or the general
principles guiding rearrangement formation.

Whole genome paired-end sequencing provided a more comprehensive analysis
of rearrangements. Paired-end genome sequencing involves reading both sides
of all randomly generated 200 bp genomic DNA fragments, thereby providing a
complete genome sequence as well as the location of any structural variations. In
the sequences of 2 lung cancer cell lines, Campbell and colleagues discovered
103

somatically

acquired

rearrangements.

Having

such

a

number

of

rearrangements allowed the extraction of some general trends: rearrangements
tended to originate from amplicons and rearrangements predominantly occur
intra-chromosomally. Of the 103 events isolated, 81 were intra-chromosomal
(Campbell et al., 2008). A subsequent study that captured 2,166 rearrangements
by analyzing 24 breast cancer genomes added additional power to these
analyses. Of more than 2,000 events, 1,708 were intra-chromosomal, and of
these, 1,574 showed breakpoints within 2Mb of one another (Stephens et al.,
2009). Paired-end sequencing of metastatic pancreatic cancer revealed a similar
bias toward intra-chromosomal events (Campbell et al., 2010). This may suggest
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that a) linear physical proximity encourages rearrangement, and b) chromosome
territories might be a determinant of rearrangement. However, since these
rearrangement profiles are from tumors, they may not be generalized to a normal
cell.

The breast cancer genome sequence also revealed that 50% of rearrangements
occur in genic regions (Stephens et al., 2009). This is significantly more than
expected to occur in genic regions, which compose just 40% of the genome.
However, rearrangements near genes are likely to alter gene expression or
function and impact proliferative or metabolic capacity. So, whether this finding
represented a bona fide predisposition to intragenic rearrangement or a
consequence of selection could not be determined.

Analysis of the rearrangement junctions from breast cancer genomes showed
that the majority had minor junctional microhomology, and 5-15% of the junctions
used greater than 4 nucleotides (Stephens et al., 2009). This implicates both
NHEJ and alt-NHEJ as the primary pathways generating rearrangements based
on microhomology utilization. However, nucleotide deletion from a break is
another important parameter in the joining process, and in this approach the
extent of end deletion cannot be assessed because the precise breakpoints were
unknown.
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Mature B Cell Lymphomas

The yearly incidence of lymphoma is about 2 per 10,000; this represents 5% of
all cancers in the US. About 95% of these cases are cancers of mature B cell
origin (Kuppers, 2005). While nearly all cancers carry cytogenetic abnormalities,
the mature B cell cancers distinguish themselves by their tendency to carry
clonal, recurrent translocations that drive tumor growth. This predisposition to
oncogenic rearrangement may be due to a relatively high DNA damage burden.
Mature B cells divide rapidly and so are prone to an increased frequency of usual
genomic insults. Perhaps more significantly, mature B cells express Activation
Induced Cytidine Deaminase (AID) that normally introduces DNA damage in
immunoglobulin genes to facilitate the antibody diversification reactions class
switch recombination and somatic hypermutation. However, AID activity may also
yield inappropriately joined physiological DSBs, off-target DSBs and off-target
mutations.
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Mature B Cell Lymphoma Origins and Pathogenesis

Developed B cells participate in the humeral immune response by producing
antibodies to recognize and bind antigen. However, B cells must first complete a
complex developmental program that includes de novo antigen receptor
construction, activation, and affinity maturation. Development begins in the bone
marrow with V(D)J recombination, which assembles the immunoglobulin heavy
and light chain genes to form an antigen binding B cell receptor, the precursor to
a secreted antibody. This process is performed at the DNA level and involves
permanent alteration of the B cell genome. After presentation of a functional B
cell receptor (BCR) on the surface, mature naïve B cells leave the bone marrow
and home to the peripheral lymphoid organs where they form germinal centers.
In germinal centers, mature naïve B cells may be activated by T cell dependent
or independent mechanisms to expand, express AID, and undergo the
immunoglobulin diversification reactions somatic hypermutation (SHM) and class
switch recombination (CSR) (Durandy, 2003). These reactions alter the affinity of
the BCR for its cognate antigen and change the effector function of the resulting
antibody, respectively. B cell cancers can arise at any stage of development.

Origins of mature B cell lymphomas. B cell lymphomas can be traced to a cellular
origin based on the B cell developmental stage they most closely resemble
(Kuppers, 2005). Mature B cells lymphomas are so called because they originate
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from B cells at this late stage of development, and therefore, show many of the
characteristics of mature B cells. For example, Burkitt’s lymphoma cells strongly
express usual germinal cell B cell surface markers CD19, CD20 and CD22, while
follicular lymphoma grows in follicles reminiscent of the germinal center
morphology (Bellan et al., 2010; Carbone et al., 2009). In fact, the majority of
mature B cell lymphomas are thought to derive from germinal center or postgerminal center cells. Consistent with this, the mature B cell lymphomas follicular
lymphoma, Burkitt's lymphoma, diffuse large-cell lymphomas, MALT lymphoma
and multiple myeloma all have hypermutated variable regions, indicating AID
activity (and thereby germinal center residence) during or before malignant
transformation (Kuppers et al., 1999). Some of the mature B cell lymphomas,
such as follicular lymphoma, even exhibit ongoing somatic hypermutation,
bolstering the case for their germinal center parentage (Bahler and Levy, 1992).

More recently, gene expression profiling has supplanted more traditional modes
of tumor characterization such as selected cell surface markers and histological
appearance. By profiling normal B cell subsets along with tumors then comparing
their gene signatures, the origins of these lymphomas can be further elucidated.
Using this method, follicular lymphoma, Burkitt’s lymphoma and most diffuse
large B cell lymphomas were shown to have a GC B cell gene expression
signature (Alizadeh et al., 2000). Interestingly, a subset of diffuse large cell
lymphoma (the activated B like DLBCL) most closely resembled in vitro activated
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B cells. It should be noted that malignant transformation might change gene
expression profiles and mask the true origin of tumors. However, together with
the observation that many of these tumors carry mutated variable regions, these
data strongly suggest that the mature B cell lymphomas indeed originate from
GC or post-GC cells.

Genetic lesions in mature B cell lymphoma. B cell lymphomas are unique among
cancers in that they almost all carry chromosomal translocations. Most of these
rearrangements involve one of the immunoglobulin loci and an oncogene (Table
1.1). Consequently, the oncogene is brought under control of the immunoglobulin
transcriptional regulatory elements thereby dysregulating its expression. For
example, in diffuse large B cell lymphoma the IgH regulatory elements may
partner with the BCL2 locus to form the IgH/BCL2 translocation. The BCL2
protein (an antiapoptosis factor) is constitutively expressed, which prevents cell
death (Weiss et al., 1987) In Burkitt’s lymphoma c-myc become constitutively
expressed and drives uncontrolled cell proliferation (Dalla-Favera et al., 1983). In
the mature B cell lymphomas unregulated expression of an oncogene is
frequently coupled with deletion or inactivation of a tumor suppressor. In other
words, a translocation provides cancer’s accelerator, while deletion or mutation
takes away the brakes. For example, in mantle cell lymphoma ATM is frequently
mutated, this disables the DNA damage response and prevents the cell from
blocking cell cycle progression in the case of genomic insult (Camacho et al.,
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2002). And, in Burkitt’s lymphoma p53 is mutated in nearly 50% of the cases
(Gaidano et al., 1991).
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Table 1.1. Genomic abnormalities in mature B cell lymphomas
Lymphoma

Chromosomal
Translocation

Tumor suppressor
gene mutations

Mantle cell lymphoma

CCND1-IgH (95)

ATM (40)

Follicular lymphoma

BCL2-IgH (90)

Diffuse large B cell
lymphoma

BCL6-various (35)
BCL2-IgH (30)
c-myc-IgH/IgL (15)

CD95 (20)
ATM (15)
p53 (25)

Burkitt’s lymphoma

c-myc-IgH/IgL (100)

p53 (40)
RB2 (20-80)

MALT lymphoma

API2-MALT1 (30)
BCL10-IgH (5)
MALT1-IgH (20)
FOXP1-IgH (10)

CD95 (80)

Lymphoplasmacytoid
lymphoma

PAX5-Igh (50)

Multiple myeloma

CCND1-IgH (20)
FGFR3-IgH (10)
MAF-IgH (10)

CD95 (10)

Table 1.1. Genomic abnormalities in mature B cell lymphomas. Each mature
B cell lymphoma subtype is shown with its associated chromosomal
translocation(s) and tumor suppressor gene mutation(s). In parentheses are the
percent of all cases in which the abnormality is estimated to exist. Adapted from
(Kuppers, 2005).
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Of the three immunoglobulin loci, the heavy chain locus most frequently serves
as a translocation partner. IgH is subject to all three of the antibody diversification
reactions, and these reactions may generate the DSBs that serve as substrates
for translocation (more on this in later sections). However, translocagenesis
requires paired double strand breaks, and the origin of oncogene DSBs in mature
B cell lymphomas has been much debated. The recurrent nature of
translocations associated with mature B cell lymphomas might simply be a result
of random events that are strongly selected. This must certainly be part of the
picture whereas tumorigenesis requires a sustained selective advantage.
However, oncogenes may also suffer specific recurrent targeted DSBs, as does
the IgH locus.
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Programmed DSBs in B Lymphocytes

B cells produce an antibody of two identical heavy and light chains. The heavy
chains are connected to one another and to the light chains by disulfide bonds.
The C-terminal portions of the heavy chains are called the constant region and
are responsible for antibody effector functions. The N-terminal portions of the
heavy and light chains compose the antigen-binding site or variable region
(Figure 1.2). Antibodies recognize antigen in an effort to neutralize and mount a
response to pathogens. However, a finite genome cannot code for a sufficient
diversity of antigen receptors. B cells create this diversity de novo by somatic
gene alteration in three reactions: V(D)J Recombination, Class Switch
Recombination (CSR) and Somatic Hypermutation (SHM). Two of these
reactions, CSR and V(D)J Recombination, involve DSB intermediates.

V(D)J Recombination. V(D)J recombination can be thought of as a “Pick 3
Lottery” where gene segments are combined in assorted permutations to
generate the variable region of antibodies. It is a site-specific recombination
reaction that, in B cells, occurs between immunoglobulin gene segments flanked
by recombination signal sequences (RSSs). RSSs consist of a conserved
heptamer and nonamer separated by either 12 or 23 bp of nonconserved
sequence. Recombination reactions may only occur between 12- and 23-RSSs
(van Gent et al., 1996). V(D)J is initiated by DSBs located between the gene
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segment and its RSS. RSSs are joined to form signal sequences while gene
segments are joined in a process that involves the alteration of sequences at the
junction, thereby introducing additionally sequence, and therefore antibody,
diversity.

A

B

Adapted from (Bothmer, 2011)

Figure 1.2. Schematic of an antibody. (A) Antibodies are composed of two
identical heavy (blue) and light (green) chains connected by disulfide bonds. (B)
The C-terminal portions of the heavy chains are called the constant region
(orange), at the N-terminus of the heavy and light chains is the antigen-binding
site (red).
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In B cells, V(D)J recombination occurs on the immunoglobulin heavy (IgH) and
light chain loci. In mice, IgH consists of hundreds of V, 13 D and 4 J gene
segments over a ~ 1 Mb region on chromosome 12. There are 2 light chain loci,
IgKappa and IgLambda, which only contain V and J segments. B cell
development begins in the bone marrow where pro-B cells undergo D-J
rearrangement followed by V-DJ rearrangement on IgH. They are now pre-B
cells, which undergo V-J rearrangement on the light chain and develop into
immature B cells.

V(D)J is catalyzed by the RAG1 and RAG2 gene products. RAGs introduce a
nick between two coding sequences and their RSSs, then catalyze a
transesterification reaction in which the 3’ hydroxyl group on the coding strand
forms closed hairpin coding ends and blunt signal ends (McBlane et al., 1995).
This process generates 4 ends that remain associated with RAGs in a postcleavage complex (Qiu et al., 2001; Tsai et al., 2002). Both signal ends and
coding ends are joined by the NHEJ machinery, requiring the activity of Ku70,
Ku80, XRCC4 and Ligase4 (Roth, 2003). However, before the coding ends are
joined, the endonuclease Artemis opens the hairpins to generate a substrate for
nucleotide addition by terminal deoxynucleotidyl transferase (TdT) (Komori et al.,
1993; Ma et al., 2002). The absence of any NHEJ factors leads to the complete
lack of V(D)J recombination and the severe-combined immunodeficiency
phenotype (Frank et al., 1998; Gu et al., 1997; Nussenzweig et al., 1996; Taccioli
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et al., 1993).

The RAG post cleavage complex is thought to shepherd the ends to joining via
the NHEJ pathway, excluding access to the ends by alt-NHEJ. This function is
mediated by RAG2, which plays an important role in protecting RAG-generated
ends from generating oncogenic rearrangements (Corneo et al., 2007; Deriano et
al., 2011).

Overview of Class Switch Recombination. After antigen receptor assembly, B
cells home to the peripheral lymphoid organs where they may undergo Class
Switch Recombination (CSR). CSR is a deletional recombination event that
exchanges an IgH constant region gene for one of several others. The constant
region of an antibody (or isotype) determines its effector function. For example,
IgG1 can activate complement while IgE causes leukocyte degranulation. In mice
there are 8 constant regions: Cμ, Cδ, Cγ3, Cγ1, Cγ2b, Cγ2a, Cε and Cα. Naive
B cells transcribe the Cμ constant region and express cell-surface IgM (IgD is
expressed by virtue of alternative splicing to Cδ). During CSR IgM is replaced by
one of the six other constant regions which code for the alternate antibody
isotypes: IgG3, IgG1, IgG2b, IgG2a, IgE and IgA. The mouse constant region
genes lie on a continuous stretch of chromosome 12. Just upstream of each
constant region lies a switch region, a highly repetitive 1-5kb DNA sequence
(Figure 1.3) (Chaudhuri and Alt, 2004).
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Adapted from freely licensed media

Figure 1.3. Schematic of class switch recombination. At top, the structure of
the IgH locus, colored rectangles represent constant region genes and black
diamonds represent repetitive switch regions. AID introduces DSBs in switch
regions and the intervening region is excised and circularized. NHEJ repairs
DSBs, juxtaposing an alternative constant region to the VDJ gene segments.
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Upon antigen encounter, B cells enter the germinal center and express AID
(Muramatsu et al., 1999). AID was discovered by a subtractive hybridization
screen in a B lymphoma cell line, and is required for CSR in mice and humans
(Muramatsu et al., 2000; Muramatsu et al., 1999). AID deaminates cytidine
residues on DNA, converting them to uracil (Dickerson et al., 2003; PetersenMahrt et al., 2002; Pham et al., 2003), primarily at WRCY motifs (W=A or T, R=A
or G, Y=C or T) (Martin et al., 2002). During somatic hypermutation, AID
introduces U:G mismatches into the immunoglobulin variable regions, which can
then be processed into an array of mutations to diversify the antigen-binding
motif (Peled et al., 2008). During CSR (which will be the focus of this section)
mismatches are processed into switch region DSBs, which are joined with
deletion of the intervening sequence (Figure 1.3) (Stavnezer et al., 2008).

AID targeting to the switch region. The mechanism by which AID targets switch
region cytidines for deamination has been long-studied and recently, the
molecular underpinning has been revealed. CSR was initially associated with
transcription by the discovery of non-coding transcripts of class switched
constant region genes in a lymphoma cell line (Stavnezer-Nordgren and Sirlin,
1986). Later work showed that certain cytokines stimulate germline transcripts
and CSR. Specifically, TGF-beta induces IgA transcripts and switching to IgA in
lipopolysaccharide (LPS) stimulated B cell cultures (Lebman et al., 1990).
Additionally, deletion of the promoters responsible for sterile transcripts abolishes
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CSR (Jung et al., 1993). Finally, AID activity on a transcribed gene has been
shown to increase proportionally with transcription (Yoshikawa et al., 2002).
Switch regions are repeat-rich and significantly enriched in guanine, so the
formation of secondary structures has been hypothesized to play a role in AID
targeting. Transcribed G-rich DNA is predisposed to forming stable RNA:DNA
hybrids in R loops. Indeed, the presence of stable RNA-DNA hybrids (R loops)
has been shown by bisulphate sequencing and has been detected in vivo (Yu et
al., 2003).

The R loop as a potential substrate for AID is consistent with AID’s activity on
ssDNA, which is exposed in the transcription bubble. Both in vivo and in vitro
assays have demonstrated that ssDNA is a high efficiency substrate for AID,
while dsDNA is not (Bransteitter et al., 2003; Chaudhuri et al., 2003; Dickerson et
al., 2003; Petersen-Mahrt et al., 2002; Pham et al., 2003; Ramiro et al., 2003;
Sohail et al., 2003). For example, incubation of dsDNA with RNA polymerase in
an in vitro transcription system with AID resulted in cytidine deamination on the
non-transcribed strand (Pham et al., 2003). In B cells, AID has been shown to
interact with PolII, demonstrating a physical interaction with the transcription
machinery (Nambu et al., 2003; Pavri et al., 2010). Interestingly, AID appears to
have activity on both the transcribed and non-transcribed DNA strand in SHM
and CSR, although only the non-template strand is single stranded. AID may
access ssDNA on the non-template strand by interaction with the ssDNA binding
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protein Replication protein A (RPA) (Chaudhuri et al., 2004). The exosome
complex may play a role in facilitating non-template strand access as well (Basu
et al., 2011).

The distribution of PolII on the IgH locus provides additional insight into the
mechanism of AID targeting. PolII ChIP experiments showed a high density of
AID-independent PolII throughout the repetitive switch region, indicative of
polymerase stalling (Rajagopal et al., 2009). Corroborating this finding, run-on
analysis (a direct measure of transcription in vivo) also detected stalled
transcripts in the switch region (Rajagopal et al., 2009). This stalling profile
matched the hypermutation distribution well; together suggesting that stalling
might precede and orchestrate AID targeting. Interestingly, G-rich switch region
repeats appear to directly encourage stalling; in their absence PolII accumulation
was not observed. Polymerase stalling results in a persistent transcription bubble
and thereby, the prolonged exposure of ssDNA (Pavri et al., 2010). Given AID’s
proclivity for deamination of ssDNA, these data provide an attractive framework
for AID targeting. Namely, switch regions bear high levels of stalled PolII, which
exposes ssDNA, a high efficiency substrate for AID.

In 2010, Pavri and collegues performed an shRNA screen for factors that
abrogate CSR in the CH12 B lymphoma cell line. They identified Suppressor of
Ty5 Homolog (Spt5), as required for CSR (Pavri et al., 2010). Spt5 is a
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transcription factor that associates with stalled PolII (Rahl et al., 2010), or PolII
that accumulates in the promoter-proximal region. They showed that Spt5 directly
associates with AID, and is required for AID recruitment to the IgH locus. ChIPSeq in B cells of Spt5 revealed marked colocalization of Spt5 and PolII, with the
IgH locus being the greatest area of enrichment for both, genome-wide.
Additionally, AID ChIP-Seq correlated well with both Spt5 and PollI ChIP-Seqs;
thousands of loci were found to load AID, and these loci also bore stalled PolII
and Spt5. The promoter-proximal regions of these genes (an established area of
stalling) were the primary sites of enrichment. Taken together, these data
suggest that AID deaminates cytosines on ssDNA exposed by stalled PolII, and
is targeted by interacting with Spt5. Indeed, the authors showed that Spt5 and
AID interact in both primary B cell and fibroblasts. To confirm, the authors
sequenced 10 genes that bore high levels of Spt5 for mutations. Generally, these
genes suffered mutation, but 10 genes represent a very limited survey. A direct
genome-wide measure of AID activity would be the ideal comparison, but the
technology for such an experiment was not available.

U:G mismatches yield switch region DSBs. The U:G mismatch introduced by AID
may be processed into DSBs. Several experimental approaches have been used
to demonstrate switch region DSBs during CSR. First, the DNA damage
response protein NBS1 and the DNA damage induced histone mark γH2AX form
AID-dependent foci at the IgH locus in stimulated B cells (Petersen et al., 2001).
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Second, linker-mediated PCR (LM-PCR), a technique to capture and amplify
genomic DSBs at a particular locus, indicates AID-dependent DSBs at the switch
regions (Schrader et al., 2005). But, how does a U:G mismatch result in a DSB?
It has been shown that proteins in the base excision repair pathway (BER) effect
this conversion. The mismatch is recognized and converted to an abasic site by
Uracil DNA Glycosylase (UNG1) (Di Noia and Neuberger, 2002; Imai et al., 2003;
Rada et al., 2002; Schrader et al., 2005). APE endonucleases can recognize this
abasic lesion and cleave the DNA backbone to generate a single strand nick
(Guikema et al., 2007). Thereafter, the precise mechanisms are unclear but it is
thought that staggered nicks are processed into DSBs. The mismatch repair
pathway, while not strictly required for class switching, may play a role in the
generation of DSBs (Bardwell et al., 2004; Martin et al., 2003; Martomo et al.,
2004; Schrader et al., 1999). Exo1 may be recruited the mismatch site by the
MSH2-MSH6 complex, which then performs nucleotide excision followed by
strand resection (Bardwell et al., 2004; Martomo et al., 2004). It has been
hypothesized that paired nicks on opposite strands might be simultaneously
resected thereby generating a DSB.

DSB repair at the switch region. DSBs in the switch region triggers the normal
DNA damage response. DSBs are recognized by the MRN complex, which is
followed by activation and accumulation of ATM, a serine/threonine kinase (Falck
et al., 2005; You et al., 2005). ATM phosphorylates multiple downstream
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effectors including the histone variant H2AX, converting it to γH2AX (Rogakou et
al., 1998). γH2AX, in concert with other histone modifications and early DNA
damage response factors, provides a scaffold for the focus formation of several
DNA damage response factors such as MDC1 and 53BP1 (Schultz et al., 2000;
Xie et al., 2007). The presence of these factors at the IgH locus in B cells
undergoing CSR has been demonstrated by immuno-FISH (Petersen et al.,
2001). The absence of these proteins results in reductions in CSR ranging from 3
fold, as in the case of ATM (Reina-San-Martin et al., 2004), to complete absence,
as in the case of 53BP1 (Ward et al., 2004).

Sequencing of switch region junctions in class switched B cells shows that the
majority do not contain significant microhomology (Yan et al., 2007), suggesting
that the NHEJ pathway carries out the deletional recombination reaction. In mice
with preassembled heavy and light chains that bear conditional deletion of the
NHEJ factors XRCC4 or Lig4, CSR still occurs at 50% of wild type levels (Yan et
al., 2007). Switch junctions in this system showed microhomology utilization,
indicating that in the absence of NHEJ alt-NHEJ can contribute to efficient CSR.
Similar results were obtained in a mouse lacking Ku70 and Lig4 (Boboila et al.,
2010b). Thus, joining of switch region DSBs usually occurs by NHEJ, but in the
absence of NHEJ pathway components, alt-NHEJ may perform the repair.

In contrast, the absence of 53BP1 results in complete abrogation of class
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switching (Manis et al., 2004; Ward et al., 2004). Instead of joining DSBs in
disparate switch regions, B cells lacking 53BP1 rejoin DSBs, producing
intraswitch deletions. It has been hypothesized that this may be the result of DNA
hypomobility in the absence of 53BP1. 53BP1 deficient cells show decreased
movement of uncapped telomeres and B cells from 53BP1-/- mice fail to perform
efficient V(D)J recombination to distal gene segments (Difilippantonio et al.,
2008; Dimitrova et al., 2008). Alternatively, 53BP1 has been shown to protect
ends from resection; in its absence, ssDNA is exposed and available for
microhomology utilization in joining (Bothmer et al., 2011; Bothmer et al., 2010).
Thus, it is hypothesized that in the absence of 53BP1 switch region DSBs are
resected, exposing switch region microhomology that is rejoined locally by the
alt-NHEJ pathway.

47

AID Mediates Mutations and Translocations in Non-Ig Genes

AID generates physiological U:G mismatches in the switch region and variable
regions to generate downstream DSBs and mutations, respectively. In the current
model, AID is targeted to these regions by a physical interaction with Spt5, a PolII
stalling factor. However, AID has been shown to mutate, translocate, and
introduce DSBs in non-Ig genes. In fact, the study of AID activity at nonimmunoglobulin loci has been instrumental in deciphering AID’s targeting
mechanism.

Several

non-Ig

targets

of

AID

have

been

implicated

in

lymphomagenesis, thereby associating AID with genomic instability in these
tumors.

AID introduces mutations in non-Ig genes. Initial studies indicated that AID
activity was associated with switch region transcription. Moreover, Ig genes could
still be mutated when replaced with another promoter (Betz et al., 1994; TumasBrundage and Manser, 1997), and non-Ig sequences were mutated when in the
context of the Ig locus. Therefore, it stood to reason that other transcribed genes
might suffer AID mediated mutation. A first study isolated memory and naïve B
cells from the peripheral blood of healthy donors and sequenced a select panel of
genes. They found that BCL-6, a gene expressed in germinal center B cells and
reported to carry mutations in non-Hodgkin’s lymphoma, was significantly
mutated (Shen et al., 1998). Importantly, the mutation spectrum was similar to
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that found in Ig genes. A subsequent study had similar findings, but also reported
that BCL-6 sequencing from B cell tumors showed that only those cancers with a
germinal

center

or

post-germinal

center

phenotype

carried

mutations

(Pasqualucci et al., 1998). Additionally, CD95 was shown to bear a similar
mutation spectrum in the GC B cells of healthy donors (Muschen et al., 2000).
Later work expanded the roster of expressed, mutated non-Ig genes to include
Pim1, c-myc, Pax5, CD79a and CD79b (Gordon et al., 2003; Pasqualucci et al.,
2001). Importantly, mutation at these loci displayed a similar profile to variable
region mutations but at a much lower frequency; a preference for transitions over
transversions and specific targeting to WRCY motifs. These papers suggested
that AID might target non-Ig genes for mutation.

A broader study of AID dependent mutation in germinal center B cells suggested
that AID might very widely mutate transcribed genes. Liu and colleagues isolated
germinal center B cells from AID deficient and wild-type mouse peyer’s patches,
then sequenced 118 genes, in a region 1.5kb downstream from the transcription
start site based on their expression in the germinal center. While mutation
frequencies were about 100 times lower than immunoglobulin mutation rates,
25% of the genes examined bore significant AID dependent mutations (Liu et al.,
2008). Consistent with previous studies, BCL6 was the most highly mutated gene
in the experimental set. Interestingly, when the same genes were sequenced in
germinal center B cells from mice lacking UNG and MSH2, several genes
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including the c-myc proto-oncogene, appeared to have increased mutations
rates. This suggested that some genes targeted by AID might undergo error-free
repair by the base excision repair and mismatch repair pathways.

This study was the most comprehensive analysis of non-Ig AID targeting at the
time, and surely demonstrated that AID triggers mutation at several locations
throughout the genome. However, low-throughput sequencing is a relatively
cumbersome technique, prohibiting its application in a truly comprehensive study.
Indeed, these experiments delivered a limited picture of AID’s role in genomic
instability. First, only genes were examined for mutation; this excluded the
possibility of discovering AID’s role in targeting non-genic regions, should it have
one. Second, from thousands of potentially mutated genes only a small percent
were examined (118 of ~25,000 or 0.5%), while these result were generalized to
conclude that 25% of all genes are mutated, it was not a true measure of AID
promiscuity. Third, the selection criteria for genes required that they be in the top
decile of microarray expression values; as such, the effects of transcription on
non-Ig AID-dependent mutations could not be effectively assessed. Fourth, they
only sequenced a 1 kb region of each gene in the same location – 1.5 kb
downstream from the transcription start site. Whether this is the primary site of
AID targeting in the gene body was unexamined. Finally, while mutations may be
a proxy for DSBs, especially in the absence of UNG, DSBs and subsequent
translocation were not directly measured. In fact, no system to perform an
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unbiased, large-scale analysis of AID dependent translocations has yet been be
devised.

Expanding on this work, a recent genome-wide study revealed the full spectrum
of potential AID targets. Yamane and colleagues performed AID-ChIP followed
by deep sequencing and showed that AID is associated with almost 6,000 genes
in activated B cells. This confirmed the assertion from Liu and colleagues that
AID might associate with 25% of all genes. As expected, the IgH locus loaded the
greatest quantity of AID, while genes previously shown to be mutated by AID or
translocated in mature B cell lymphomas appeared throughout the list. For
example, mir-142 (a translocation partner of c-myc and mutation target of AID
(Gauwerky et al., 1989; Robbiani et al., 2009)) was among the 15 genes with the
greatest AID levels. Importantly, the presence of AID as determined by ChIP-Seq
was predictive of AID-mediated mutation, suggesting that AID both binds and
mutates promiscuously (Yamane et al., 2011).

When compared to histone modification and PolII ChIP-Seq landscapes, several
trends emerged. AID was shown to primarily associate with transcribed genes as
determined by mRNA-Seq, and to associate with open chromatin as determined
by the histone modification H3K4 trimethylation. Within the gene body, AID
bound predominantly at the promoter proximal sequence, and colocalized with
putative sites of RNA PolII accumulation and stalling. This meshed well with
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previous data suggesting that AID targeting depends on PolII stalling and ssDNA
availability (Pavri et al., 2010; Rajagopal et al., 2009). However, this study was
marked by some limitations. First, AID association is a substitute evaluation for
AID activity, so while AID ChIP-Seq may define sites of AID association it is not a
direct measure of activity. Second, after surveying 13 AID associated genes for
mutations, it was concluded that AID ChIP-Seq is a good proxy for AID activity,
but this is a relatively small-scale analsis. Third, the authors conclude that AID
association correlates well with AID-mediated mutation, but the question of AID
mediated translocations and DSBs was left unaddressed.

AID-mediated translocations. AID is also responsible for initiating translocations,
events commonly observed in mature B cell lymphomas. For instance, formation
of the c-myc/IgH translocation (a hallmark of Burkitt’s lymphoma) in the IL-6
induced plasmacytoma lymphoma model, requires the presence of AID (Ramiro
et al., 2004). Moreover, the same translocation occurs in primary B cell in culture
within hours of AID expression, and only in the presence of UNG (Ramiro et al.,
2006). The requirement for UNG indicates that the conversion of U:G
mismatches to DSBs is required for translocation, and strongly implicates AID in
directly initiating the DSB.

Translocations require paired DSBs (Richardson and Jasin, 2000), and while AID
had been conclusively shown to initiate DSBs in IgH, the etiology of the DSB in c-
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myc

was

unclear.

Fragile

DNA

elements

prone

to

form

non-B-DNA

configurations, including Z-DNA, triple-helical H-DNA, and G-quadruplex DNA
have been proposed to account for breaks in c-myc (Liu and Levens, 2006;
Marcu et al., 1992; Wierstra and Alves, 2008). Recently, direct evidence for AID
generating the DSBs in c-myc came from genetic experiments using the sitespecific yeast meganuclease I-SceI. In mice bearing I-SceI sites in both IgH and
c-myc I-SceI is sufficient to produce c-myc/IgH translocations, and when I-SceI is
only present at IgH, I-SceI and AID together produce c-myc/IgH translocations.
However, in the absence of AID, I-SceI-mediated DSBs in IgH did not generate cmyc/IgH translocations (Robbiani et al., 2008). Thus, AID is responsible for the
breaks in c-myc that partner with IgH to form the c-myc/IgH translocation.

AID’s ability to introduce DSBs at IgH and non-Ig loci such as c-myc may play a
role in mature B cell lymphomagenesis in vivo. In humans, AID is expressed in
mature B cells lymphomas that carry translocations to IgH. For example, AID is
expressed in activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL)
(Lenz et al., 2007) and, ABC-DLBCL has a high frequency of illegitimate switch
region recombinations and deletions, as well as translocations involving IgH
(Lenz et al., 2007) to genes targeted for mutation by AID, such as c-myc and
BCL6. These findings associate AID with lymphomagenesis, but a mouse model
finally proved that AID causes mature B cell lymphomas,
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Several transgenic mice constitutively over-expressing AID have been generated
and many of these mice develop cancer. However, the tumors are not of B cell
origin, instead they are epithelial tumors and T cell lymphomas (Muto et al., 2006;
Okazaki et al., 2003; Shen et al., 2008). These tumors carried mutations in
oncogenes, but did not bear any translocations (Okazaki et al., 2003).
Additionally, in conflict with the IL-6 induced plasmacytoma mouse (which bore
tumors only in the presence of AID), mice with a B cell specific AID transgene did
not succumb to any tumors (Muto et al., 2006). In 2009, Robbiani and colleagues
published the first direct evidence that AID contributes to lymphomagenesis in
vivo. p53-/- mice overexpressing AID from a transgene in B cells by virtue of V
kappa promoter succumbed quickly to mature B cell lymphomas (Robbiani et al.,
2009). This was in contrast to the control group of p53-/- mice, which perished
from T cell lymphomas and sarcomas. Important, B cell lymphomas in these mice
carried clonal reciprocal translocations, including the c-myc/IgH translocation
observed in Burkitt’s lymphoma. This mouse model also yielded tumors bearing a
clonal translocation between c-myc and mir-142. The c-myc/mir-142 translocation
juxtaposes the c-myc coding region to the mir-142 regulatory elements, thereby
dysregulating c-myc expression. Sequencing of the mir-142 locus from germinal
center B cells in WT and AID-/- mice revealed that mir-142 is a bona fide target of
AID. This discovery provided further evidence for AID’s role in lymphomagenesis
in humans; the c-myc/mir142 translocation has been reported in a human
aggressive B cell leukemia (Gauwerky et al., 1989).
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These studies nicely show that AID is capable of initiating DSBs and
translocations. However, to date c-myc and mir142 are the only genes
conclusively shown to suffer AID dependent translocation. B cells overexpressing
AID harbor high levels of translocations and chromosome breaks (Robbiani et al.,
2009). But, the entire array of genes susceptible to DSBs by AID is unknown
because a method for high-resolution unbiased mapping of DSBs or their
resulting translocations does not exist.
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CHAPTER 2:
Translocation Capture Sequencing
Recent

deep-sequencing

studies

have

revealed

hundreds

of

genomic

rearrangements in human cancers (Campbell et al., 2008; Pleasance et al.,
2010a; Pleasance et al., 2010b; Stephens et al., 2009). These studies have shed
some light on the nature and extent of genomic abnormalities. However,
rearrangements from tumors may be highly selected, and cancer cells might
have altered DNA repair pathways that give rise to a different rearrangement
profile. Thus, the physiologic constraints that govern the genesis of these events
remain unclear because methods for mapping chromosomal translocations in
primary cells do not yet exist. Here, we sought to develop a genome-wide
strategy to document chromosomal rearrangements in short-term cultures of
primary cells.

In our system, DSBs are induced at the c-myc (chromosome 15) or IgH
(chromosome

12)

loci,

which

were

engineered

to

harbor

the

I-SceI

meganuclease target site (Robbiani et al., 2008) (c-mycI-SceI/I-SceI or IgHI-SceI/I-SceI B
cells respectively, hereafter referred to as MycI and IgHI) (Figure 2.1). I-SceI, an
intron encoded endonuclease present in the mitochondria of Saccharomyces
cerevisiae, recognizes an 18 base pair sequence absent from the mouse
genome. The I-SceI break system was first developed in mammalian cells to
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examine DSB resolution (Rouet et al., 1994). It has since been widely used to
study many aspects of DSB repair including DSB end processing, chromosomal
translocation, pathway selection, and to perform gene targeting (Bothmer et al.,
2010; Brunet et al., 2009; Windbichler et al., 2007). Here, the unique break at ISceI sites serves as bait for other endogenous breaks in the cell, thereby
generating rearrangements with one known partner.
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Figure 2.1. Schematic of loci containing I-SceI sites. The IgH locus of IgHI B
cells is shown below, while the c-myc locus from MycI B cells is shown above.
Each is displayed with the site-specific primers used for TC-seq and their
approximate distance from the I-SceI site. Nested primers were placed at least
150 bp from the I-SceI site to allow for capture of events generated from
moderately resected ends.
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To generate genomic DNA bearing rearrangements to I-SceI sites, mouse
splenic B cells were isolated by immunomagnetic depletion with CD43 beads and
stimulated to undergo isotype switching in cultures with LPS and IL-4. The CD43
antigen is expressed on most T cells, NK cells, granulocytes, monocytes, and
macrophages, on hematopoietic stem cells, and platelets. Among B cells, CD43
is expressed on activated B cells and plasma cells but not on resting B cells
(naive B cells) (from Miltenyi Biotech). On culture days one and two activated B
cells were infected with retroviruses to express I-SceI (with mCherry by virtue of
an embedded IRES element), and in some cases AID (with GFP by virtue of an
embedded IRES element). On day 4 singly infected cells were harvested for
genomic DNA while doubly infected cultures were sorted for double positive cells
then harvested (Figure 2.2).
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Figure 2.2. Schematic of concept for rearrangement generation. B cells
bearing I-SceI sites are isolated and infected with retroviruses to express I-SceI
endonuclease with or without AID. I-SceI cleaves the target sequence, which may
then join to endogenous DSBs to generate chromosomal rearrangements with
one known partner. Alternatively, the I-SceI induced break might religate and
assume the conformation of the native locus.
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We sought a method to isolate and sequence rearranged I-SceI sites. Of course,
classical PCR could not be utilized; rearrangements to the I-SceI site only contain
one known partner sequence. Essentially, this task requires a mechanism for
amplifying a genomic region using only one site-specific primer. A solution was
developed in 1989 to perform in vivo footprinting of enhancers and methylation
analysis (Mueller and Wold, 1989; Pfeifer et al., 1989). By ligating DNA to double
stranded linkers then using primers that anneal to the sequence of interest and
the linker, one can perform single-sided PCR (dubbed ligation-mediated PCR or
LM-PCR). Since then, this technique has been used in various applications
including the investigation of genetically programmed DSBs in lymphocytes and
HIV integration site mapping (Papavasiliou and Schatz, 2000; Schroder et al.,
2002; Zhu and Roth, 1995). We designed linkers to allow for high-fidelity PCR
with low background by including the following features.

1) Strand asymmetry; to allow for novel sequence generation in the case of
site-specific primer extension (Figure 2.3).
2) Thymine tail; to prevent linker-linker dimer formation, and to accommodate
genomic DNA fragment adenine tailing so that intermolecular ligation
events do not occur (Figure 2.3).
3) Dideoxycytosine block; to prevent double stranded linker generation in the
absence of site-specific primer extension (Figure 2.3)
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4) AscI cleavage site; to remove linkers prior to deep-sequencing.
Additionally, AscI cleavage will leave an 8 nucleotide barcode on
fragments, indicating that it was a product of linker-mediated amplification
(Figure 2.3).
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Figure 2.3. Structure of LM-PCR linker. The double stranded asymmetric linker
(dsaLinker) for LM-PCR contains a T-tail, 5’ overhang, AscI site and a
dideoxycytosine blocked 3’ end.
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First, genomic DNA was sonicated to a mean size of 800 bp, blunted, A-tailed
and ligated to dsaLinkers. Then, purified I-SceI enzyme was applied to eliminate
unrearranged target loci. (Figure 2.4A). Each sample was then divided into 2
equal parts, for TC-Seq with either forward or reverse primers. Forward and
reverse preparations were processed separately for the entire protocol. DNA was
subjected to single-primer PCR with biotinylated site-specific primers. This step
generates a complete double stranded linker on genomic DNA fragments
containing the I-SceI adjacent sequence (Figure 2.4B).
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Figure 2.4. Translocation sequencing schematic I. (A) To prepare genomic
DNA for TC-Seq it is sonicated, blunted, A-tailed, ligated to dsaLinkers and cut
with I-SceI. (B) Single-primer PCR. Prepared genomic DNA fragments were
subjected to 15 cycles of PCR with a single biotinylated primer annealing either
upstream or downstream of the I-SceI site (pIgHF1, pIgHR1, pMycF1 or pMycR1)
(Figure 2.1).
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Next, PCR reactions were spiked with primer that anneals to the newly generated
linker sequence. Higher molecular weight products were isolated from the
reaction by agarose gel electrophoresis followed by streptavidin bead purification.
A semi-nested PCR was performed (with primers pLinker and pIgHF2, pIgHR2,
pMycF2 or pMycR2) (Figure 2.1), and higher molecular weight products were
isolated by agarose gel electrophoresis. Finally, linkers were removed by AscI
digestion and fragments were assembled into an Illumina library for Paired End
deep-sequencing. 36x36 or 54x54 nucleotide sequencing was performed on an
Illumina GAII (Figure 2.5) (See methods for an in-depth TC-Seq protocol
including primer sequences).
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Figure 2.5. Translocation sequencing schematic II. Following LM-PCR,
products were isolated by strepavidin coated magnetic bead purification and
subjected to semi-nested LM-PCR. Linkers were cleaved off fragments by
digestion with the restriction endonuclease AscI then were processed into pairedend libraries for deep sequencing.

66

TC-Seq libraries were generated from 50 million B cells each. Experiments were
performed in duplicate (biological replicates) for a total of 100 million B cells
assayed per condition. To determine AID’s contribution to the genomic
rearrangement landscape TC-Seq libraries to IgH and c-myc were assembled
from AID deficient, AID sufficient and AID over-expressing (by retroviral infection)
B cells (Table 2.1). Illumina sequencing runs were repeated on some samples
(technical replicates) to increase depth and ensure saturation.

Next, sequencing data were mined for useful reads. Each end of the paired-end
sequences was matched against the relevant bait primer (IgHF2, IgHR2, MycF2
or MycR2) plus genomic sequences allowing up to two mismatches with the
bowtie short read aligner. For read pairs longer than 2 x 36 nts, 10 nts were
trimmed off the 3’ end of each read. Each read pair with a single match to one of
the site-specific primers was then checked for a perfect match to the linker
barcode on the second arm. After AscI cleavage, eight nucleotides remain ligated
to the genomic DNA, this was termed the “barcode” and it indicates linker-specific
amplification. If the barcode was present, this arm was designated a target arm,
linker sequence was trimmed, and the remainder was aligned against the mouse
genome (NCBI 37/mm9) with bowtie allowing up to 2 mismatches and requiring
unique alignments in the best alignment stratum (command line options: -v2 --all
--best --strata -m1). Exactly identical alignments (same position, same strand)
were combined into a single putative rearrangement event, events supported by
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a single alignment were not considered in any analyses. Since TC-Seq involves
multiple rounds of PCR, it is unlikely that individual reads represent actual
biological events. We also removed reads closer than 1 kb to their respective
bait; these alignments represent rejoining of the I-SceI break, uncut, or
unrearranged loci. Rearrangement positions are given as the position of the 5’
end of the read in the alignment. It should be noted that these reads are
displaced from the actual rearrangement breakpoints. Based on the distance of
the primers from the I-SceI site and agarose gel size selection, the average
displacement is expected to be ~250 bp. For all analyses, data from technical
and biological repeats were pooled to increase saturation (Table 2.1).
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Table 2.1. Data quantity per experiment. Bait – the locus containing I-SceI for
each experiment. AID – the status of activation induced cytidine deaminase
(wt=wild type, ko=knockout, rv=retroviral over-expression). Replicate – indicates
which biological replicate the data set represents, identical letters indicate
technical replicates of the same experiment, biological replicates are indicated by
different letters. Sequenced pairs – total number of paired reads obtained. Valid
pairs – total number of paired reads containing a matched linker and site-specific
primer. Left – number of valid aligned reads paired with a forward primer. Right –
number of valid aligned reads paired with a reverse primer. Total – total number
of valid, aligned reads paired with a site-specific primer, for tabulated rows (gray
shading) this value is the sum of the replicate experiments. Rearrangements [>1
kb from bait; >= 2 alignments] – total number of valid, aligned, unique reads
represented by more than 1 read instance and lying greater than 1kb from the
associated site-specific primer, for tabulated rows (gray shading) this value is the
sum of the replicate experiments.
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Table 2.1. Data quantity per experiment.
Rearrangements
[>1kb from
bait; >= 2
alignments]

bait

AID

Replicate

sequenced
pairs

valid pairs

left

right

total

cMyc

ko

A

37,496,617

16,759,723

4,071,732

6,600,751

10,672,483

16,172

cMyc

ko

B

31,561,878

16,112,165

5,763,288

5,113,161

10,876,449

14,816

A+B

28,548

cMyc

rv

A

42,942,899

13,132,287

2,610,943

458,513

3,069,456

25,653

cMyc

rv

A

39,981,085

12,332,625

2,979,621

513,095

3,492,716

26,465

6,562,172

39,789

6,561,025

27,001

13,123,197

63,772

A
cMyc

rv

B

39,119,951

15,277,084

4,997,453

1,563,572

A+B
IgH

rv

A

35,443,959

11,779,691

1,448,672

2,315,695

3,764,367

35,167

IgH

rv

A

10,860,307

2,797,362

212,458

970,485

1,182,943

21,677

IgH

rv

A

16,897,163

4,582,262

386,947

1,531,206

1,918,153

26,455

6,865,463

43,315

474,447

19,720

7,339,910

51,312

A
IgH

rv

B

5,586,756

1,820,820

247,532

226,915

IgH

ko

A

42,015,461

9,945,416

890,202

4,233,574

5,123,776

67,156

IgH

ko

B

12,289,033

2,723,023

701,452

334,221

1,035,673

1,247

IgH

wt

A

40,136,125

20,570,387

5,169,695

2,536,311

7,706,006

31,601

IgH

wt

B

25,885,221

8,005,979

1,507,154

1,665,017

3,172,171

14,104

10,878,177

37,945

A+B

A+B

A+B
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CHAPTER 3:
AID-Independent Rearrangements In
Activated B Cells

In the absence of AID, DSBs arise as by-products of normal cellular metabolism
including transcription, oxidative stress and DNA replication (Branzei and Foiani,
2010). To examine the distribution of AID-independent DSBs that lead to
rearrangements we examined rearrangements to I-SceI sites in c-myc, in the
absence of AID.

Consistent with a global distribution of DSBs, we mapped

28,548 unique rearrangements between the I-SceI site and every chromosome in
MycIAID-/- B cells (100 million cells assayed, Figure 3.1).
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Figure 3.1. Genomewide view of rearrangements to MycI in AID-/- B cells.
Rearrangements were mapped according to genomic position and displayed by
the Circos circular visualization software package (http://circos.ca). Each line
originating from c-myc on chromosome 15 represents a single rearrangement
event. The red arrow indicates the I-SceI site embedded in c-myc.
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To determine whether there is a genome-wide bias for rearrangement, these
events were characterized based on location, transcriptional status and histone
modification of the locus. First, we examined chromosomal location and found a
marked enrichment of intra-chromosomal rearrangements on chromosome 15,
with

approximately

125

events

per

mappable

megabase

(11,066

rearrangements), or ~40% of all events genomewide (Figure 3.2). In contrast,
translocations between MycI and other chromosomes were evenly distributed
throughout the genome (Figure 3.2).

Figure 3.2. Rearrangements to each chromosome in MycIAID-/- B cells.
Rearrangement partners to I-SceI sites in c-myc were binned based on
chromosome, each bin was divided by the number of mappable megabases of
sequence for that chromosome in the mm9 genome build.
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Notably, 86.7% (9,591 of 11,066) of all intra-chromosomal rearrangements were
localized within a 350 kb domain surrounding the I-SceI site (from -50 kb to +300
kb; Figure 3.3). This is consistent with the observation that 92% of intrachromosomal rearrangements in the breast cancer genome involve aberrant
joining of DSBs within 2 Mb of each other (Stephens et al., 2009), and that 87%
of RAG-mediated intra-chromosomal rearrangements in Abl-transformed pre-B
cells lie within 200 kb of a recombination substrate (Mahowald et al., 2009). The
asymmetrical distribution of events in the direction of c-myc transcription and the
adjacent Pvt1 gene is also consistent with the idea that gene expression
facilitates rearrangement (Thomas and Rothstein, 1989). I-SceI-proximal events
may be the result of either resection and rejoining of I-SceI breaks, bona fide
rearrangements between I-SceI and random DSBs, or a combination of DNA end
resection and balanced translocations. Regardless of the precise molecular
mechanism, the abundance of these events reveals a strong preference for
DSBs to be resolved by ligation to a proximal sequence, a DNA repair strategy
that may minimize gross genomic alterations.
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Figure 3.3. Profile of rearrangements around the c-myc I-SceI site. Local
rearrangements in MycI were mapped in 5 kb bins around the I-SceI site. Black
dots represent values at individual bins, the red line represents a smoothed
moving average of bin contents. Data were plotted on a logarithmic scale. Below,
schematic of the c-myc locus containing the position of the adjacent gene, pvt1.
Arrows indicate the direction of transcription.
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Recent cancer genome sequencing experiments uncovered a modest but highly
significant preference for cancer-associated rearrangements to occur in genes,
which compose only 41% of the human genome. For example, in 24 sequenced
breast cancer genomes, 50% of all rearrangements involved genes (Stephens et
al., 2009). Whether this bias resulted from selection or some inherent feature of
DSB formation and repair specific to cancer cells could not be determined. To
ascertain whether a similar bias is seen in primary cells in short term cultures,
AID-independent rearrangements in MycIAID-/- B lymphocytes (excluding 1 Mb of
DNA around the I-SceI site) were classified as genic or intergenic. Local events
were omitted from the analysis because of the observed bias for events around
the break. Consistent with the human tumor studies, 51% (9,677 of 19,246) of the
events were associated with genes (Figure 3.4A). Because only 40% of the
mouse genome is genic, this represents a small (1.25-fold) but significant
difference (permutation test P < 0.001) relative to intergenic regions.

Next, we performed a composite density analysis of rearrangements to genes
and intergenic regions. In this approach events are mapped along the gene body
or regions between genes but, instead of mapping by nucleotide position they are
mapped according to distance from the transcription start site as a percent of the
entire locus body. For example, a translocation that maps to base 250 of a 1000
bp gene would be given the value of 25%. Finally, all genes and intergenic
regions are combined to generate a merged graph of reads along all gene bodies
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and intergenic spans. Using this approach we find that genic rearrangements
were particularly enriched at transcription start sites (TSS) (Figure 3.4B).
Importantly, there appears to be no enrichment at any length along the composite
intergenic region, indication that the TSS is indeed unique in its enrichment.
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A

B

Figure 3.4. Rearrangements to genic and intergenic regions.
(A) Rearrangements, excluding the 1 Mb around I-SceI, were categorized as
genic or intergenic for each sample. (B) Composite density profile of genomic
rearrangements from MycI to genes (red line) and intergenic (blue line) regions.
TSS = transcription start site, TTS = transcription termination site.
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Next,

we

asked

whether

transcriptional

activity

is

a

determinant

of

rearrangement. mRNA-Seq data from LPS and IL-4 activated B cells was divided
into quintiles of expression and the number of rearrangements to each quintile
was tabulated (Yamane et al., 2011). We then performed 1000 computational
Monte Carlo experiments to determine the expected value in each transcription
quintile assuming a random distribution along the genome, using their average as
an expected frequency. Finally, we calculated relative frequency in each quintile
(fe) – this number indicates the percent divergence of the observed value from
the expected. Consistent with the preference for genic rearrangements, there
was a bias to transcribed genes. Fewer rearrangements than expected occurred
at silent (fe = 0.74, P < 0.001) and trace (fe = 0.95, P < 0.001) transcribed genes,
while more than expected occurred at low (fe = 1.08 P < 0.001), medium (fe =
1.13, P < 0.001), and highly (fe = 1.14, P < 0.001) transcribed genes (Figures
3.5A and 3.5B).
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Figure 3.5. Rearrangements in transcription level gene groups. (A) Genes
were divided into silent (0 FPKM (fragments per kilobase of exon per million
fragments mapped)) and expressed genes based on mRNA-Seq (Yamane et al.,
2011). The expressed group showed a bimodal distribution and was subdivided
into trace expressed genes (<= 4.04 FPKM) and more highly expressed genes
using a normal mixture model. The higher group was divided again into tertiles
(low > 4.04 FPKM; medium > 23.5 FPKM; high > 65 FPKM). (B) Relative
frequency (fe) of rearrangements in genes that are either silent or display trace,
low, medium or high levels of transcription in activated B cells as determined by
RNA-Seq. Dashed line indicates the expected rearrangement frequency based
on a random model. P < 0.001 for all (permutation test).
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To confirm a bias for transcription and open chromatin, we categorized genes as
either bearing or lacking rearrangements. Next, we asked whether genes in these
two categories were overrepresented or underrepresented in the population of
genes that bear activating histone marks and PolII as determined from ChIP-Seq
on these entities in LPS and IL-4 activated B cells (Yamane et al., 2011). We find
that rearrangements occur more frequently than expected (in a random
distribution model) to genes bearing PolII and the activating histone marks H3K4
trimethylation, H3 acetylation, and H3K36 trimethylation (P < 0.001 for all, Figure
3.6). Similarly, rearrangements occur less frequently than expected to genes that
do not load PolII or carry activating histone marks. Thus, there is a propensity for
a DSB to recombine with gene rich regions of the genome and more specifically
to transcription start sites of actively transcribed genes.
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Figure 3.6. Rearrangements in activating histone mark- and PolIIassociated gene groups. Relative frequency of rearrangements in PolII, H3K4
trimethylation, H3 acetylation and H3K36 trimethylation-associated gene groups
(Yamane et al., 2011). Dashed line indicates expected frequency based on a
random model. P < 0.001 for all samples (permutation test).
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CHAPTER 4:
Rearrangements to c-myc and IgH in the
Presence of AID

Processing of AID induced U:G mismatches can result in DSBs in Ig and non-Ig
genes such as c-myc (Robbiani et al., 2008). To determine whether AIDmediated DSBs can be captured by TC-Seq we examined the IgH and c-myc loci
in B cells expressing retrovirally encoded AID (IgHIAIDRV or MycIAIDRV). IgHI B
cells expressing both I-SceI and AID showed extensive AID-dependent
rearrangement between the I-SceI site and downstream switch (S) regions
(Figure 4.1). The frequency of rearrangements resembled the pattern of AIDmediated CSR in LPS+IL-4 cultures (e.g. IgG1>>IgG3>IgE), with 18,686 mapping
to Sγ1, 3,192 to Sγ3, and 1,433 to Sε (Table 4.1). Notably, rearrangements
mapped preferentially to the switch regions of the immunoglobulin constant
region genes, which is the physiological site of AID activity.
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Figure 4.1. Rearrangements from IgHI to downstream switch regions.
Rearrangements per kb to I-SceI sites (indicated with an asterisk) in IgH in AID-/(top panel) or AIDRV cells (bottom panel). White boxes in the schematics below
each graph represent Ig switch domains while black boxes depict constant
regions.
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Table 4.1. Rearrangement abundance in specific loci.
Rearrangements
Gene
Ig mu
Ig gamma3
Ig gamma1
Ig gamma2b
Ig gamma2a
Ig epsilon
Ig alpha
c-myc

Location
chr12:114644476114668744
chr12:114594089114606686
chr12:114563338114582604
chr12:114542220114557966
chr12:114525733114535551
chr12:114507208114518138
chr12:114496093114499984
chr15:6181448661825559

IgHI
AIDRV

IgHI
AIDWT

c-mycI
AID-/-

c-mycI
AIDRV

8,475

7,849

5

3,463

3,192

4,682

2

253

18,686

11,723

0

2,209

284

513

0

19

61

240

0

4

1,433

372

1

14

10

5

0

1

45

3

7,386

5,404

Table 4.1. Rearrangement abundance in specific loci. Total rearrangements
to immunoglobulin constant domains (switch + constant) and c-myc. 100 million
B cells were used per experiment.
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Furthermore, TC-Seq detected translocations between c-myc and IgH, and these
were entirely dependent on AID (Figures 4.2 and Table 4.1). In two biological
replicate samples totaling 100 million B cells, we observed 45 translocations from
IgHI to c-myc (the I-SceI DSB was in IgH), and 5,925 from MycI to IgH (the I-SceI
DSB was in c-myc) (Table 4.1). Additionally, TC-Seq tags mapping to c-myc from
IgHI correlate well with c-myc/IgH translocation breakpoints sequenced from
primary B cells (Figure 4.2) (Robbiani et al., 2008). This suggests that TC-Seq
reads are an accurate proxy for breakpoints. Furthermore, the data corroborate
previous findings showing that AID induced breaks at c-myc are rate limiting for
c-myc/IgH translocations (Robbiani et al., 2008) and suggest that AID-dependent
IgH breaks are two orders of magnitude more frequent than those at c-myc. We
conclude that TC-Seq captures rearrangements and translocations between
DSBs in IgHI or MycI and known AID targets.
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Figure 4.2. Screenshots of c-myc/IgH translocations. Rearrangements per kb
to I-SceI sites in c-myc in AID-/- or AIDRV cells (top panel). White boxes in the
schematics below each graph represent Ig switch domains while black boxes
depict constant regions. Translocations per 100 bp from IgHI to c-myc in AID-/- or
AIDRV cells (bottom panel). Green arrows indicate c-myc/IgH translocation
breakpoints sequenced from primary B cells (Robbiani et al., 2008).
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As was the case for AID deficient samples, MycIAIDRV and IgHIAIDRV libraries
were enriched in intra-chromosomal rearrangements: 17% (10,633 of 63,772
total events) for MycI and 70% (36,019 of 51,312) for IgHI (Figure 4.3A and 4.3B).
The latter likely had more rearrangements on chromosome 12 due to the activity
of AID at the IgH locus (Figure 4.3).

A

B

Figure 4.3 Chromosomal distribution of rearrangements in AID-sufficient
MycI and IgHI B cell genomes. (A) Bar graph displaying total rearrangements
per mappable megabase per chromosome in MycIAIDRV and (B) IgHIAIDRV B
lymphocytes. In both cases cells were transduced with retroviruses (RV)
expressing AID.
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Expression of AID did not alter the distribution of events around MycI, with 72.5%
(7,707 of 10,633) mapping within -50 kb to 300 kb of the break (Figure 4.4). A
notable exception was an additional cluster of rearrangements associated with
Pvt1 exon 5 (Figure 4.4). These events coincided precisely with documented
chromosomal translocations isolated from AID sufficient mouse plasmacytomas
(Cory et al., 1985; Huppi et al., 1990) and likely represent an AID hotspot.

Figure 4.4. Profile of local rearrangements in MycI B lymphocytes, in the
presence and absence of AID. Rearrangements per 5 kb around MycI, I-SceI
site indicated with an asterisk. Distribution in the absence (gray line) or presence
(red line) of AID. Green arrows indicate plasmacytoma translocation breakpoints.
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In agreement with the MycIAID-/- samples, translocations between IgHI or MycI
and other chromosomes were evenly distributed throughout the genome, except
for the MycI capture sample, which displayed a marked bias for chromosome 12
due to creation of DSBs at the IgH locus by AID (Figure 4.1). Similar to MycIAID-/samples, rearrangements in both cases were more likely to occur in regions that
are genic, transcriptionally active, recruiting PolII, and associated with activating
histone marks (Figures 4.5 and 4.6A). Furthermore, intragenic rearrangements
were enriched at transcription start sites of genes (Figure 4.6B).
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Figure 4.5 Rearrangements to transcription-level gene groups in AIDRV B
cells. Relative frequency of rearrangements in transcription-level gene groups to
I-SceI sites in AID sufficient B cells. IgHIAIDRV is on the left while MycIAIDRV is on
the right. Dashed line indicates expected frequency based on a random model.
Asterisks highlight values with a P < 0.001 (permutation test).
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A

B

Figure 4.6. Rearrangements to histone and PolII-associated gene groups
and gene body distribution in AID sufficient cells. (A) Relative frequency of
rearrangements in PolII-associated or activating histone mark-associated gene
groups (Yamane et al., 2011). IgHI (left) or MycI (right) AIDRV captures. Dashed
line indicates expected frequency based on a random model. P < 0.001 for all
(permutation test). (B) Composite density profile of rearrangements, genic (red)
and intergenic (blue) regions in IgHI (upper) or MycI (lower) AIDRV captures.
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In contrast to recent studies that used Nbs1 as an indirect marker of AID
mediated damage (Staszewski et al., 2011), we found little or no difference in
rearrangements to genomic repeats in the presence of AID (Table 4.2). Thus,
AID does not dramatically alter the general profile of rearrangements.

Table 4.2. Rearrangements in intergenic repeats in MycIAIDRV and MycIAID-/samples.
Repeat

MycIAID-/-

MycIAIDRV

Frequency
MycIAID-/-

Type

Frequency

p-value

MycIAIDRV

CA

507

0.0271

1528

0.028

0.5361

LINE

1084

0.0579

3137

0.0574

0.197

SINE

862

0.0461

2645

0.0484

0.7991

Others

2610

0.1395

7048

0.1291

0.0003

Total

18707

54605

Table 4.2. Rearrangements in intergenic repeats in MycIAIDRV and MycIAID-/samples. For each category, the number of events in each repeat type and the
fraction of all events falling in that type are shown. A Fisher‘s exact test was
performed to compare AID sufficient and AID deficient frequencies. Total =
number of rearrangements analyzed in that sample.
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Next, we examined whether IgHI and MycI capture DSB targets at similar rates.
Indeed, in AID sufficient samples, total translocations from a given chromosome
to IgHI or MycI occurred at roughly similar frequencies (Figure 4.7).

Figure 4.7. Translocations from MycI and IgHI to transchromosomal targets.
Graph comparing the number of translocations per mappable megabase to each
chromosome from IgHI (y axis) or MycI (x axis).

This similarity could be explained by the close physical proximity of IgH and cmyc, as suggested by studies with EBV-transformed B lymphoblastoid cells (Roix
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et al., 2003). Alternatively, the correlation in trans-chromosomal joining might
represent random ligation between I-SceI DSBs in IgH or c-myc and DSBs on
other chromosomes. This might also be a function of gene density; chromosome
7 and 11 are relatively gene rich while chromosome 3 is relatively gene poor. We
conclude that extra-chromosomal DSBs ligate DSBs in IgHI and MycI at similar
rates.

To examine the nature of the intra-chromosomal rearrangement bias we
calculated the ratio of IgHI to MycI captured events for each 500 kb segment of
the genome and compared the values for chromosome 12 and 15 to the transchromosomal joining average of 500kb windows genome-wide (Figure 4.8A).
This analysis revealed that DSBs are preferentially captured intra-chromosomally
and this effect diminishes at a rate inversely proportional to the distance from the
I-SceI site (d-1.29) (Figure 4.8B). This effect was most prominent locally but was
evident at up to ~50 Mb away from the I-SceI break. We conclude that paired
DSBs are preferentially joined intra-chromosomally and that the magnitude of this
effect decreases with increasing distance between the two lesions.
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Figure 4.8. Distance dependent intra-chromosomal rearrangements.
(A) Ratio of IgHI captured to MycI captured events in 500 kb bins moving away
from the I-SceI capture site (both directions combined). Dotted line represents
the average trans-chromosomal joining frequency computed on all chromosomes
other than 12 or 15. Gray areas show 2 standard deviations around the mean.
(B) Modeling intra-chromosomal rearrangement bias. Rearrangements to IgHI
(red) and MycI (blue) in the combined AIDRV samples were sorted into variablesized bins of ≥20 events. Rearrangement density was calculated per bin to the
left and right of c-myc separately as a step plot. When both directions were
combined and plotted as a scatter plot on a log-log scale (inset graph, hotspots in
grey) from 5 kb to 1 Mb, a roughly linear relationship suggested that the
rearrangement density decreased as a function of a power of the distance.
Fitting a linear model to the log transformed data excluding hotspots allowed the
exponent of this power law to be estimated as approximately -1.3 (R2=0.81).
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CHAPTER 5:
Rearrangement Hotspots in Activated B
Cells

To determine whether there are hotspots for rearrangement, we searched the B
cell genome for local accumulations of reads in AID deficient and sufficient
samples. TC-Seq hotspots were defined as a localized enrichment of
rearrangements above what is expected from a uniform genomic distribution. We
removed likely artifacts; namely hotspots containing >80% of reads within DNA
repeats, and those with footprints of <100nt (because translocations are
amplified from randomly sonicated DNA (Figure 2.4A), deep-sequence tags
associated with bona fide rearrangements are unlikely to map within a small
region). We chose to omit these repeat alignments because while repeats may
be analyzed in bulk (Table 4.2), the alignments from the reads may not be
reliable. We identified 34 hotspots captured by MycI in the absence of AID (Table
5.1). There were 31 hotspots in 17 genes and 3 in non-genic regions. 17 of the
hotspots were in Pvt1, within 500 kb of the I-SceI site.
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Table 5.1. TC-Seq hotspot list for MycIAIDKO B cells.
Hotspot position
chr15:6186860661882447
chr15:6193760561948372
chr15:6188420961895375
chr17:3998004239983459
chr15:6190510161913127
chr15:6189678461903467
chr2:155630784155631968
chr7:112726654112731060
chr15:6191929261924833
chr15:6192858261933207
chr15:8173512481735608
chr15:6195018861954544
chr15:6191445161917481
chr1:137751600137752931
chr15:6199607361999322
chr9:107230861107231335
chr15:1621919516219312
chr1:3770446837704668
chr15:6205024962052811
chr14:4609617046097095
chr15:6198953161991172
chr2:155633401155634287
chrX:1137687811378216
chr15:6202542862027589

Total
Rearrangements

Closest gene
id|name

Closest
gene (nts)

Repeat type and
cryptic I-SceI

61

19296|Pvt1

in gene

all

48

19296|Pvt1

in gene

all

37

19296|Pvt1

in gene

36

751530|Mir715

in gene

27

19296|Pvt1

in gene

all

26

19296|Pvt1

in gene

line, sine, LTR, DNA,
simple, DNA

26

17391|Mmp24

in gene

19

11785|Apbb1

in gene

sine, line, near cryptic
IsceI site

18

19296|Pvt1

in gene

sine, ltr

17

19296|Pvt1

in gene

line, sine, LTR, DNA,
simple (GT, GA)

14

11429|Aco2

in gene

12

19296|Pvt1

in gene

11

19296|Pvt1

in gene

11

21956|Tnnt2

2762

8

19296|Pvt1

in gene

7

69536|Hemk1

in gene

sine

7

12565|Cdh9

488543

near cryptic IsceI site

7

72097|2010300
C02Rik

in gene

7

19296|Pvt1

in gene

6

218952|Fermt2

in gene

6

19296|Pvt1

in gene

5

17391|Mmp24

in gene

5

71458|Bcor

235647

5

19296|Pvt1

in gene

100

near cryptic IsceI site

sine, line
LTR, near cryptic
IsceI site
line, ltr, simple
(CCAA)

chr15:6198700061987927
chr15:6207536162075946
chr8:9645091496451204
chr7:68722486872359
chr19:4437540544375796
chr2:132665496132665672
chr15:6197515161975421
chr6:8534626185346531
chr15:6204241962042698
chr7:8088479580885210

5

19296|Pvt1

in gene

4

19296|Pvt1

in gene

line

4

14681|Gnao1

in gene

simple (CA)

4

57775|Usp29

in gene

simple (ca)

4

20250|Scd2

in gene

near cryptic IsceI site

3

66634|Mcm8

in gene

Sine, Simple (GT)

3

19296|Pvt1

in gene

3

52055|Rab11fi
p5

21633

3

19296|Pvt1

in gene

3

100038347|Fa
m174b

in gene

Table 5.1. TC-Seq hotspot list for MycIAIDKO B cells. For each hotspot the
number of rearrangements constituting the hotspot, the closest gene, the
distance to that gene, and the type of repetitive DNA elements contained in the
hotspot are shown. Hotspots attributed to cryptic I-SceI sites are indicated in the
last column.
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In addition, 2 hotspots occurred within 5 kb of cryptic I-SceI sites (each bearing
one mismatch to the 18- base pair recognition sequence). For example, one such
hotspot at chr15:16219195-16219312 containing a 1-off I-SceI recognition
sequence bore 8 rearrangements (Figure 5.1). A genome-wide search for
rearrangements within 5 kb of cryptic I-SceI sites (83 within the mouse genome
with 1 or 2 mismatches to the canonical I-SceI recognition sequence) yielded 57
events, 7 times more than expected in a random distribution model. When
allowing up to 6 mismatches we find a total of 5 out of 17 AID-independent
hotspots near putative cryptic I-SceI sites. Although I-SceI has been used to
generate a unique DSB in gene targeting and DNA repair experiments, our data
suggest that DNA recognition by I-SceI can be promiscuous in the mouse
genome, as demonstrated for other yeast endonucleases (Argast et al., 1998).

Next, we searched the AID sufficient data sets for AID dependent hotspots.
These were defined as genomic locations where there was at least a 10-fold
enrichment over background rearrangement levels. In contrast to AID-/-, we found
157 hotspots in 83 genes captured by IgHIAIDRV and 60 hotspots in 37 genes by
MycIAIDRV in 100 million B cells. (Tables 5.2 and 5.3). This suggests that AID is
generating targeted genomic instability above background levels.
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Figure 5.1. I-SceI cryptic site screenshot. Screenshot showing a TC-Seq
hotspot associated with a cryptic I-SceI site located on chromosome 15 in
MycIAID-/- B cells. Rearrangements accumulate within 200 bp of a site that differs
by 1 base (T->G) from the canonical I-SceI recognition sequence.
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Table 5.2. TC-Seq hotspots in MycIAIDRV B cells.

Hotspot position

Total
Rearrangements

Closest gene
id|name

Closest
gene
(nts)

chr12:114569045-114578835
chr12:114600202-114603869
chr7:132695991-132699453
chr13:43880182-43885076
chr15:62001300-62004099
chr15:74761629-74764081
chr11:61466811-61469564
chr15:62009859-62012742
chr15:74785846-74789190
chr17:29627912-29629491
chr12:114665845-114667844
chr15:82040871-82042918
chr10:53793003-53795422
chr7:52091757-52092909
chr15:34012782-34013570
chr15:79724869-79726419
chr16:84706683-84708187
chr4:44714489-44715772
chr16:84703741-84705601
chr8:129115681-129117132
chr15:62157722-62158587
chr16:19061770-19063197
chr7:132747538-132748234
chr4:44716165-44717120
chr11:87569331-87570257
chr15:62000011-62000612
chr4:44722019-44722683
chr6:70676375-70677272
chr9:44333604-44334132
chr4:44981291-44982237
chr11:86398867-86399824
chr15:74827015-74828130
chr11:61470062-61470857
chr8:35871344-35872045
chr6:129134035-129135134
chr15:62160533-62161287
chr15:61903483-61904141

2063
259
141
132
128
85
74
69
57
49
48
28
27
25
24
23
20
20
19
17
15
14
13
13
12
11
11
11
9
9
9
8
7
7
7
6
6

IgH|IgH
IgH|IgH
16190|Il4ra
12522|Cd83
19296|Pvt1
17069|Ly6e
71520|Grap
19296|Pvt1
17069|Ly6e
18712|Pim1
IgH|IgH
20788|Srebf2
17155|Man1a
14204|Il4i1
67154|Mtdh
80287|Apobec3
387173|Mir155
18507|Pax5
387173|Mir155
270110|Irf2bp2
19296|Pvt1
IgLlambda|IgLlambda
60504|Il21r
18507|Pax5
387160|Mir142
19296|Pvt1
18507|Pax5
IgLkappa|IgLkappa
12145|Cxcr5
76238|Grhpr
75909|Tmem49
110454|Ly6a
71520|Grap
319520|Dusp4
93694|Clec2d
19296|Pvt1
19296|Pvt1

in gene
in gene
in gene
in gene
in gene
21399
in gene
in gene
in gene
in gene
in gene
5481
in gene
in gene
in gene
in gene
6197
in gene
8783
in gene
75192
in gene
in gene
in gene
108
in gene
in gene
in gene
in gene
12045
in gene
in gene
in gene
in gene
in gene
78003
in gene
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chr15:74784468-74785172
chr7:132750068-132750375
chr8:73223046-73223403
chr9:107199973-107201059
chr8:87501360-87502454
chr15:82980236-82980359
chr12:114550576-114550791
chr3:95463197-95463519
chr10:17443755-17444131
chr10:59681817-59682230
chr10:59680759-59681209
chr12:114551620-114552139
chr15:79913571-79914224
chr6:127100691-127101260
chr15:61897189-61897630
chr15:74756575-74757098
chr15:62156632-62157160
chr13:46059069-46059856
chr12:114566773-114567144
chr15:62020486-62020920
chr9:44143288-44143844
chr17:35138064-35138737
chr15:62105382-62105511

6
6
6
6
6
5
5
5
5
5
5
5
5
4
4
4
4
4
4
4
4
4
3

17069|Ly6e
60504|Il21r
16478|Jund
12700|Cish
16477|Junb
104307|Rnu12
IgH|IgH
17210|Mcl1
17684|Cited2
53374|Chst3
53374|Chst3
IgH|IgH
27367|Rpl3
12444|Ccnd2
19296|Pvt1
17069|Ly6e
19296|Pvt1
20238|Atxn1
IgH|IgH
19296|Pvt1
15270|H2afx
22321|Vars
19296|Pvt1

308
in gene
in gene
in gene
in gene
12
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
28382
74102
in gene
in gene
in gene
in gene
in gene
22852

Table 5.2. TC-Seq hotspots in MycIAIDRV B cells. For each hotspot the
genomic location (chromosome:base#-base#), the number of events in that
hotspot and its most proximal gene is shown. If a hotspot is in a gene the last
column indicates this, if the hotspot is in an intergenic region the last column
gives the number of bases away from the nearest gene. Only AID-dependent
hotspots are shown.
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Table 5.3. TC-Seq hotspots in IgHIAIDRV B cells. (Pages 106-109)
Hotspot position
chr12:114563677-114583617
chr12:114592880-114605961
chr12:114464291-114473409
chr7:132695160-132701616
chr12:113826127-113831888
chr12:114477632-114487105
chr13:43880627-43885981
chr12:114545002-114549279
chr16:84703733-84708651
chr11:61466722-61471367
chr12:114550562-114553023
chr12:114487888-114495960
chr6:129131713-129135370
chr6:70672635-70676968
chr12:81210545-81214030
chr17:29627857-29630975
chr12:114529738-114534115
chr12:114460798-114463471
chr7:132746979-132749248
chr16:58715676-58718789
chr7:52091646-52094659
chr8:129115389-129117233
chr15:61817197-61819111
chr12:116745900-116747837
chr10:53793549-53795607
chr12:115526476-115529230
chr11:87569636-87571044
chr12:115984499-115986323
chr12:114560586-114562879
chr12:116861441-116863848
chr12:117150666-117151414
chr12:88539032-88541058
chr12:115821793-115822684
chr12:114096947-114100451
chr16:19061101-19062590
chr12:116152849-116154287
chr13:63896445-63900869
chr3:135352008-135353935
chr9:107199367-107200994
chr17:51970428-51972180
chr12:114606862-114609279
chr12:114557649-114560033
chr3:95462675-95465208
chr11:106173700-106175830
chr12:114835673-114836176
chr11:115487516-115488927
chr12:116886227-116888201
chr12:115097413-115098823

Total
Rearrangements
18010
3415
397
355
306
198
158
149
142
129
120
103
95
90
89
74
61
60
58
52
49
43
42
38
38
35
31
29
29
27
27
27
26
26
26
25
25
24
20
20
20
19
19
19
18
18
17
17
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Closest gene id|name

Closest
gene (nts)

IgH|IgH
IgH|IgH
IgH|IgH
16190|Il4ra
70435|Inf2
IgH|IgH
12522|Cd83
IgH|IgH
387173|Mir155
71520|Grap
IgH|IgH
IgH|IgH
93694|Clec2d
IgLkappa|IgLkappa
12192|Zfp36l1
18712|Pim1
IgH|IgH
69195|Tmem121
60504|Il21r
71223|Gpr15
100328588|Nup62-il4i1
270110|Irf2bp2
17869|Myc
IgH|IgH
17155|Man1a
IgH|IgH
387160|Mir142
IgH|IgH
IgH|IgH
IgH|IgH
IgH|IgH
382620|Tmed8
IgH|IgH
56696|Gpr132
IgLlambda|IgLlambda
IgH|IgH
76251|0610007P08Rik
18033|Nfkb1
12700|Cish
20230|Satb1
IgH|IgH
IgH|IgH
17210|Mcl1
15985|Cd79b
IgH|IgH
67283|Slc25a19
IgH|IgH
IgH|IgH

in gene
in gene
24991
in gene
in gene
11295
in gene
in gene
5733
in gene
in gene
2440
in gene
in gene
in gene
in gene
in gene
33065
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
15758
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene

chr11:86398657-86400144
chr16:19065068-19066725
chr8:35870456-35872041
chr12:70298030-70299253
chr8:73223130-73224638
chr12:117158582-117159779
chr12:115630002-115631365
chr9:107201768-107203198
chr14:122361101-122363562
chr12:116532327-116532749
chr12:116383843-116384804
chr12:56591584-56593525
chr12:117086102-117086768
chr12:70397988-70398524
chr4:44725889-44726961
chr7:133556483-133558100
chr13:53014444-53014988
chr12:115560605-115561181
chr4:44980880-44981502
chr13:23713187-23714124
chr3:96073011-96074020
chr12:87027653-87028719
chr4:44715829-44717064
chr2:158492484-158494071
chr13:53072809-53074649
chr9:44333703-44334267
chr12:115076892-115077564
chr12:115391414-115392751
chr2:166888980-166890860
chr12:115776774-115777349
chr8:87501548-87502456
chr12:114610038-114611149
chr9:44412166-44412743
chr16:58672312-58673522
chr1:108068896-108070111
chr12:115232761-115233011
chr12:115707425-115707742
chr12:114955011-114955614
chr6:136752518-136753244
chr12:114555430-114556333
chr10:59681922-59682995
chr12:116175390-116175840
chr12:115008112-115009040
chr8:97269761-97270072
chr12:116733901-116734666
chr12:117072263-117072562
chr6:129130592-129131098
chr12:115717148-115717715
chr12:116229318-116230137
chr4:44714015-44714884
chr12:114553758-114554896
chr15:74785673-74786897
chr16:10784789-10785123

17
17
15
15
15
14
14
13
13
12
12
12
11
11
11
10
10
10
10
10
10
10
10
10
10
10
9
9
9
9
9
8
8
8
8
8
8
8
8
8
8
7
7
7
7
7
7
7
7
7
7
7
7
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75909|Tmem49
IgLlambda|IgLlambda
319520|Dusp4
109065|1110034A24Rik
16478|Jund
IgH|IgH
IgH|IgH
12700|Cish
321019|Gpr183
IgH|IgH
IgH|IgH
18035|Nfkbia
IgH|IgH
69554|Klhdc2
18507|Pax5
12478|Cd19
11992|Auh
IgH|IgH
76238|Grhpr
50709|Hist1h1e
319189|Hist2h2bb
53314|Batf
18507|Pax5
228852|Ppp1r16b
18030|Nfil3
12145|Cxcr5
IgH|IgH
IgH|IgH
68949|1500012F01Rik
IgH|IgH
16477|Junb
IgH|IgH
13209|Ddx6
12892|Cpox
98432|Phlpp1
IgH|IgH
IgH|IgH
IgH|IgH
320332|Hist4h4
IgH|IgH
53374|Chst3
IgH|IgH
IgH|IgH
20299|Ccl22
IgH|IgH
IgH|IgH
93694|Clec2d
IgH|IgH
IgH|IgH
18507|Pax5
IgH|IgH
17069|Ly6e
12703|Socs1

in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
2577
in gene
in gene
in gene
12780
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
231
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene

chr15:74763628-74764024
chr12:115134720-115134990
chr7:132750171-132750297
chr17:35136839-35137019
chr12:116831379-116831823
chr4:44721635-44722251
chr12:115414770-115415436
chr15:79911701-79912444
chr13:51942199-51943030
chr6:48655721-48656684
chr15:82041126-82042151
chr1:36365470-36366278
chr12:116396756-116396922
chr11:5421596-5421866
chr12:116930165-116930446
chr12:115251470-115251824
chr3:96024349-96024764
chr15:74787652-74788420
chr12:114729327-114730211
chr12:114497586-114498517
chr6:48696841-48697785
chr11:61472162-61473172
chr12:55797689-55797969
chr12:117107309-117107806
chr12:92827477-92828227
chr2:34812256-34812641
chr12:115609552-115610249
chr12:115855867-115856592
chr6:48634895-48635772
chr12:115117746-115118111
chr9:32347803-32348302
chr2:127952144-127952647
chr12:115298061-115298583
chr12:113858703-113859237
chr17:88463676-88464261
chr1:162966442-162967042
chr13:21871724-21872334
chr15:34012549-34013176
chr6:48689187-48689841
chr7:108257838-108258501
chr16:10783339-10784041
chr10:59413651-59414365
chr14:70688210-70689003
chr12:115252782-115253686
chr4:134479505-134480566
chr12:115187722-115188045
chr13:63895201-63895639
chr16:58720437-58720884
chr7:132634208-132634668
chr12:116011816-116012535
chr10:59634442-59634618
chr12:117238411-117238513
chr1:38720806-38720934

7
6
6
6
6
6
6
6
6
6
6
5
5
5
5
5
5
5
5
5
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
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17069|Ly6e
IgH|IgH
60504|Il21r
22321|Vars
IgH|IgH
18507|Pax5
IgH|IgH
27367|Rpl3
23882|Gadd45g
231931|Gimap6
20788|Srebf2
214855|Arid5a
IgH|IgH
22433|Xbp1
IgH|IgH
IgH|IgH
319176|Hist2h2ac
17069|Ly6e
IgH|IgH
IgH|IgH
317757|Gimap5
71520|Grap
66266|Eapp
IgH|IgH
83602|Gtf2a1
22029|Traf1
IgH|IgH
IgH|IgH
107526|Gimap4
IgH|IgH
14247|Fli1
12125|Bcl2l11
IgH|IgH
11565|Adssl1
225055|Fbxo11
14455|Gas5
56702|Hist1h1b
67154|Mtdh
16205|Gimap1
207278|Fchsd2
12703|Socs1
74747|Ddit4
19057|Ppp3cc
IgH|IgH
27981|D4Wsu53e
IgH|IgH
76251|0610007P08Rik
71223|Gpr15
67711|Nsmce1
IgH|IgH
53374|Chst3
IgH|IgH
16764|Aff3

21456
in gene
in gene
832
in gene
in gene
in gene
in gene
in gene
in gene
5736
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
837
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
in gene
20988
1600
in gene
in gene
9657
in gene
in gene

chr4:44724505-44724640
chr12:116550486-116550640
chr5:114281912-114282032

3
3
3

18507|Pax5
IgH|IgH
20345|Selplg

1193
in gene
1402

Table 5.3. TC-Seq hotspots in IgHIAIDRV B cells. For each hotspot the
genomic location (chromosome:base#-base#), the number of events in that
hotspot and its most proximal gene is shown. If a hotspot is in a gene the last
column indicates this, if the hotspot is in an intergenic region the last column
gives the number of bases away from the nearest gene. Only AID-dependent
hotspots are shown.

Next, we sought to characterize the nature of AID targets. Consistent with a
translocation coupled targeting mechanism, 80% of the AID-dependent hotspots
captured by c-myc and 90% of those captured by IgH were within genes. For
example, we found robust AID-dependent hotspots on Il4i1 and Pax5 (a recurring
IgH translocation partner in lymphoplasmacytoid lymphoma (Kuppers, 2005))
(Figure 5.2 and Tables 5.2 and 5.3).
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Figure 5.2. Screenshots of AID-dependent rearrangement hotspots.
Translocations per 100 bp present at Il4i1 and Pax5 genes in all samples. Arrows
indicate the direction of transcription. Black boxes represent exons while lines
represent introns.
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AID-dependent hotspots were similar for IgHI B cells expressing wild type levels
(WT) or retrovirally over-expressed (RV) AID, however the number of TC-Seq
captured events per hotspot was decreased in the former (Figures 5.2 and 5.3).
Therefore, translocations to AID targets occur in cells expressing physiological
levels of AID and hotspots are not dependent on AID over-expression. 3 hotspots
observed in AIDWT samples but not AIDRV samples are likely due to experimental
variability. We conclude that AID produces substrates for translocations in a
number of discreet sites throughout the genome, and these sites are mainly in
genes.

Figure 5.3. Overlap of hotspots in AIDWT and AIDRV IgHI samples. Venn
diagram showing the number of shared and exclusive AID-dependent hotspotbearing genes in IgHIAIDRV and IgHIAIDWT experiments.
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Consistant with equal capture rates of extrachromosomal targets by c-myc and
IgH (Figure 4.7) Genes containing AID-dependent hotspots overlapped between
IgHIAIDRV and MycIAIDRV samples (Figure 5.4).

Figure 5.4. Overlap of hotspots in IgHIAIDRV, MycIAIDRV and MycIAIDKO
samples. Venn diagram showing the number of shared and exclusive AIDdependent hotspot-bearing genes in the three experiments.

We found that 28 of the frequently translocated targets were shared. In contrast,
there were a number of unique intra-chromosomal AID-dependent hotspots. For
example, rearrangements to Inf2 on chromosome 12 (~850 kb from IgHI) were
only found by IgHI capture while rearrangements near Pvt1 on chromosome 15
(up to ~350 kb from MycI) were only found by MycI capture (Tables 5.2 and 5.3).
Thus, there is a bias towards recombination between I-SceI breaks and AID
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hotspots within the same chromosome. Additionally, the finding that some
hotspots are only captured in cis indicates that TC-Seq underestimates the
number of AID mediated DSBs in the genome and suggests that we have not
reached saturation. Additionally, we note that AID-independent hotspots do not
arise in the AID-sufficient sample. We propose that this is due to a higher
availability of AID-generated DSBs, which saturate the rearrangement profile to ISceI generated ends.

Combined analysis of the IgHI and MycI TC-Seq data sets and mRNA-Seq data
shows that AID dependent hotspots are primarily found in transcribed genes
(Figure 5.5A). However, while nearly all of the translocated genes are actively
transcribed, there is no clear correlation between transcript abundance and
rearrangement frequency (Figure 5.5B). Furthermore, ~2000 highly transcribed
genes are not rearranged (Figure 5.5A, shaded area). Therefore transcription is
necessary but not sufficient for AID targeting, and transcription levels alone
cannot account for AID-dependent DSBs.
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A

B

Figure 5.5. Correlating AID dependent hotspots with transcription.
(A) Empirical cumulative distribution analysis showing transcript abundance in
genes displaying (red) or lacking (black) AID dependent rearrangement hotspots.
Filled-in gray slice represents ~2000 highly transcribed yet unrearranged genes.
(B) Total rearrangements as a function of gene expression (mRNA-Seq)
(Yamane et al., 2011) in genes bearing AID dependent rearrangement hotspots.
Each gene is plotted as one point.
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Additionally, AID-dependent hotspots are biased to the region around the
transcription start site (Figure 5.6A). This finding is consistent with the
accumulation of AID and Spt5 around the promoters of stalled genes and the
distribution of somatic hypermutation (Pavri et al., 2010; Yamane et al., 2011).
Indeed, AID-dependent TC-Seq hotspots overlap with regions of AID and Spt5
accumulation (Figures 5.6B and 5.7).

A

B

Figure 5.6. Genomic features at AID-dependent hotspots. (A) Composite
density graph showing the distribution of rearrangements in genes associated
with AID dependent hotspots relative to the TSS. (B) Spt5 and AID recruitment at
genomic sites associated with translocation hotspots (Pavri et al., 2010; Yamane
et al., 2011).
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Figure 5.7. AID loading at AID-dependent rearrangement hotspots.
Empirical cumulative distribution function showing AID accumulation at TSSs of
genes displaying (red) or lacking (black) AID-dependent TC-Seq hotspots. AID
association data was derived from AID ChIP-Seq experiments (Yamane et al.,
2011).

This correlation prompted us to explore the relationship between AID activity and
accumulation

of

chromosomal

translocations

by

measuring

somatic

hypermutation at TC-Seq captured AID targets (Yamane et al., 2011) (Table 5.4).
To increase sensitivity we examined AID mediated mutations in IgKAID/UNG-/- B
cells (AID over expression by virtue of a VKappa promoter increases AID levels
and therefore, mutation rates). In the absence of UNG mutation rates are further
increased because U:G mismatches are processed into mutations rather than
116

DSBs (Schrader et al., 2005; Xue et al., 2006). We found a positive correlation
(Spearman coefficient = 0.84) between hypermutation and rearrangement
frequency (Figure 5.8). All genes analyzed with a mutation frequency over 10x105

bear rearrangements, and all genes with AID-dependent TC-Seq hotspots show

mutations (Figure 5.8). Rearrangements were only seen rarely in genes with
lower rates of mutation. This suggests that the frequency of hypermutation and
the frequency of AID-induced DSBs are directly proportional. We conclude that
AID-dependent TC-Seq hotspots occur on stalled genes that can accumulate
Spt5, AID, and may suffer hypermutation relative to background levels.
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Pim1
Mir142
Myc
Jh4
intron
Il4ra
Nfkb1
Mir21
Grap
Mir155
Csk
Pax5
Hist1h1c
Ly6e
Cd83
H2afx
Gadd45g
Apobec3
Clec2d

521
0
286
0
41
1
43
1
171
3
26
2
35
2
26
0
27
0
19
0
26
0
31
5
81
4
34
3
13
0
7
0
12
0
13
1
18
0
22
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1996

P value

26101
26369
18255
28270
20453
17219
21551
23676
103818
19136
17223
14640
29062
25257
22734
12838
25583
23454
19084
12402
27677
31614
37807
33267
114476
28035
42680
34266
20583
13546
11577
38378
23611
18630
23728
27482
37505
16440
50996

Aicda-/- Mutation
frequency (x 10-5)

IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/-

IgkAID-Ung-/Mutation frequency
(x 10-5)

Mutations

IgSg1

bp sequenced

IgSm

Strain

Gene

Table 5.4. Hypermutation analysis. (Pages 118-120)

1.00E-08
<1

1567

1.00E-08
<1

200.5

1.00E-08
5.8

199.5

1.00E-08
4.22

164.7

2.17E-06
15.7

151.0

1.00E-08
13.7

120

5.36E-08
7.92

114.37

1.28E-05
0

105.53

2.60E-08
0

99.6

1.55E-04
<1

93.94

1.00E-08
0

82.00

3.92E-05
15.03

70.70

9.00E-04
14.27

79.7

2.52E-06
8.8

63.2

2.61E-03
<1

60.5

3.59E-05
<1

55.1

1.81E-03
<1

54.8

5.25E-04
3.6

47.99

3.10E-03
0

43.14

1.20E-07

Ikzf1
Il4i1
Adrbk1
Hvcn1
Bcl11a
Actb
Ucp2
Gpr15
Pip5k1c
Dpagt1
Lman1
Sfrs9
Trex1
Blr1
IgCm
Cdc42
Hmbs
Eif3h
Rpl4
Rbbp7
Crk
Spib
Fam50a
Aicda
Gdi2

Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/IgkAID-Ung-/Aicda-/-

67695
34994
36302
41757
55503
23333
17277
24912
21033
38265
34092
25984
23858
22139
27937
37789
29540
36102
56600
26430
48791
29569
36662
32871
37790
34574
27625
36549
38924
45906
25726
28015
22838
28566
34058
33048
30948
34352
30600
22472
26602
27511
28215
28941
27684
34086
32154
35479
25717
31044
30772

1
15
4
14
3
8
0
8
3
12
2
7
0
5
0
7
2
6
1
4
1
3
1
3
2
3
0
3
1
4
0
2
0
2
0
2
0
2
0
1
0
1
1
1
0
1
2
1
0
0
2
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1.47
42.86

1.05E-02
11.02

38.3

1.14E-03
5.4

34.3

2.45E-02
<1

32.1

2.45E-01
14.3

31.36

1.50E-02
5.87

26.9

1.62E-02
<1

22.6

1.69E-02
<1

18.52

3.15E-01
6.77

16.6

3.16E-02
1.8

15.1

5.48E-02
2.1

10.14

3.31E-01
2.72

9.12

6.69E-01
5.29

8.68

2.59E-01
<1

8.21

5.73E-01
2.57

8.71

3.29E-01
<1

7.14

5.05E-01
<1

7.00

2.08E-01
<1

6.05

5.01E-01
<1

5.82

5.02E-01
<1

4.44

4.58E-01
<1

3.63

1.00E+00
3.54

3.45

1.00E+00
0

2.93

6.14E-01
6.22

2.82

1.00E+00
0

<1

2.48E-01
6.5

IgkAID-Ung-/45462
Aicda-/31251
IgkAID-Ung-/34173
Repeat
1*
Aicda-/na
IgkAID-Ung-/39636
Repeat
2**
Aicda-/na
IgkAID-Ung-/48809
Repeat
3***
Aicda-/na
IgkAID-Ung-/48237
Serinc3
Aicda-/na
IgkAID-Ung-/46081
Mir715
Aicda-/44285
*chr19:28,942,810-28,943,877
N-myc

0
0
3
_
0
_
1
_
2
_
11
14

<1

1.00E+00
<1

8.73
_
0.00

_
_
_

_
2.05

_
_

4.15

_
_

23.87

5.51E-01
31.61

**chr11:27,022,268-27,023,001
***chr2:98,506,321-98,507,533

Table 5.4. Hypermutation analysis. Genes were analyzed using DNA isolated
from IgkAID/Ung-/- or Aicda-/- LPS + IL-4activated B cells (Robbiani et al., 2009).
Genes marked in yellow were analyzed de novo and added to a previous
hypermutation survey (Yamane et al., 2011). bp: total number of bp sequenced.
Mutations: total number of mutations detected. p value was calculated between
the mutation frequency obtained in IgkAID/Ung-/- and Aicda-/-.
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Figure 5.8. Translocation frequency versus mutation frequency in AID
targeted genes. Each gene was plotted as a function of its mutation rate in
IgKAID/Ung-/- B cells and its rearrangement frequency as determined by TC-Seq.

Among AID-dependent hotspot containing genes we find several that are
translocated or deleted in mature B cell lymphoma. These include Pax5/IgH,
Pim1/Bcl6, Il21r/Bcl6, Gas5/Bcl6 and Ddx6/IgH translocations and Junb and
Socs1 deletions in diffuse large B cell lymphoma, Birc3/Malt1 translocation in
MALT lymphoma, Ccnd2/IgK translocation and Bcl2l11 deletion in mantle cell
lymphoma, Aff3/Bcl2 and Grhpr/Bcl6 translocations in follicular lymphoma,
mir142/c-myc translocation in B cell prolymphocytic leukemia as well as cmyc/IgH and Pvt1/IgK translocations in Burkitt’s lymphoma (Table 5.5).
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Table 5.5. AID-dependent rearrangements in human B cell lymphoma.
TC-Seq Gene

Translocation in Mature BCL

Mature BCL
Type

Reference

Birc3 (Api2)
Il21r
Pax5
Pim1
Aff3
Gas5
Ccnd2
c-myc
Ddx6 (Rck)
Grhpr
Bcl2l11
Socs1
Junb
mir142
Pvt1
IgH
IgK
IgL

t(11;18)(q21;q21)
t(3;16)(q27;p11)
t(9;14)(p13;q32)
t(3;6)(q27;p21.2)
t(2;18)(q11.2;q21)
t(1;3)(q25;q27)
t(2;12)(p12;p13)
t(8;14)(q23;q32)
t(11;14)(q23;q32)
t(3;9)(q27;p11)
Deleted
Deleted
Deleted
t(8;17)
t(2;8)(p11.2;q24.1)
several
several
several

MALT
DLBCL
DBLCL
DLBCL
FL
DLBCL
MCL
BL
DLBCL
FL
MCL
DLBCL
DLBCL
B-PLL
BL
several
several
several

(Rosebeck et al., 2011)
(Ueda et al., 2002)
(Iida et al., 1999)
(Yoshida et al., 1999)
(Impera et al., 2008)
(Nakamura et al., 2008)
(Gesk et al., 2006)
(Kuppers, 2005)
(Lu and Yunis, 1992)
(Akasaka et al., 2003)
(Bea et al., 2009)
(Mottok et al., 2009)
(Mao et al., 2002)
(Gauwerky et al., 1989)
(Einerson et al., 2006)
(Kuppers, 2005)
(Kuppers, 2005)
(Kuppers, 2005)

Table 5.5. AID-dependent rearrangements in human B cell lymphoma.
Genes bearing AID-dependent TC-Seq hotspots are shown with the associated
translocation or deletion observed in human mature B cell lymphoma (BCL). BCL
types are abbreviated as follows: MALT (mucosa-associated lymphoid tissue
lymphoma), DLBCL (diffuse large B cell lymphoma), FL (follicular lymphoma),
MCL (mantle cell lymphoma), BL (Burkitt’s lymphoma), B-PLL (B cell
prolymphocytic leukemia).
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Interestingly, we find that AID is capable of inducing DSBs in Fli1 (Table 5.3),
which is translocated to EWS in 90% of Ewing’s sarcomas, a malignant tumor of
uncertain origin (Riggi and Stamenkovic, 2007). We conclude that in addition to
mutating many genes, AID also initiates DSBs in numerous non-Ig genes. These
genes serve as substrates for translocations associated with mature B-cell
lymphoma, strongly implicating AID as a source of genomic instability in these
cancers.
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CHAPTER 6:
Discussion
To date, the study of chromosomal aberrations has been primarily limited to
events identified in tumors and tumor cell lines. Although we have learned a great
deal about the importance of genomic rearrangements in cancer, it has not been
possible to develop an understanding of the cellular and molecular forces that
govern their genesis. To examine genomic rearrangements in primary cells in
short term cultures, we developed a technique to catalog these events by deep
sequencing, TC-Seq. Using this technique we have obtained the complete
recombinomes of two genes, c-myc and IgH, in activated B cells in the presence
and absence of AID. Our analysis of over 180,000 rearrangements reveal the
importance of transcription, chromosome territories and physical proximity in
recombinogenesis, and identifies hotspots for AID-mediated translocations in
mature B cells. Our data also suggest that non-Ig DSBs induced by AID are an
important source of genomic instability in the mature B cell lymphomas. Finally,
TC-Seq is a widely applicable technique; it can be adapted to study translocation
biology is any tissue or cell type and to discover the location and nature of other
DNA damage sources.

124

Nuclear Proximity and Chromosomal Position

The

existence

of

chromosome

territories,

regions

in

which

individual

chromosomes segregate, has been long proposed (Cremer and Cremer, 2001)
and recently shown to be a key feature of genome organization and determinant
locus proximity (Lieberman-Aiden et al., 2009). However, until now the degree to
which this impacts the genomic rearrangement landscape was unclear. Our
analysis provides evidence that physical proximity and chromosome territories
are partial determinants for joining of rearrangement partners. First, we find that
rearrangements tend to occur intra-chromosomally. For example, when a DSB is
introduced in c-myc 40% of rearrangements to that site occur on chromosome
15. This observation is consistent with the analysis of rearrangements in breast
cancer genomes, which showed that 92% of events occur intra-chromosomally
and involve joining of DSBs within 2 Mb of each other (Stephens et al., 2009).
Furthermore, since our experiments were performed in primary cells we can
conclude that this phenomenon is a basic feature of rearrangement, not a result
of cancer cell specific effects or selection.

We find that the effects of physical proximity are most evident in the 350 kb
region around a DSB. In both the absence and presence of AID, the plurality of
rearrangements fall in this region. Interestingly, this marked preference for DSB
repair within 350 kb matches the range of γH2AX spreading from a DSB
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(Bothmer et al., 2010; Savic et al., 2009). γH2AX is a marker of the DNA damage
response, which has been shown to spread widely around the site of a DSB,
perhaps marking the extent of the DNA damage focus. It has been hypothesized
that that the DNA damage response facilitates proximal rearrangement, a
phenomenon most prominent at the IgH locus during CSR. (Bothmer et al.,
2011). Our observed preference for local repair might reflect this fact.

The magnitude of the effect of chromosome territories on rearrangement is far
less prominent than proximal joining, but is consistent with recent genome
mapping data obtained by high-throughput chromosome conformation capture
(Hi-C) (Lieberman-Aiden et al., 2009). When compared to trans-chromosomal
joining, we find that a bias to intra-chromosomal rearrangements is evident even
when as much as 50 Mb separates DSBs. In mouse, the mean autosome size is
~130 Mb, so a 50 Mb preference for intra-chromosomal joining on either side of a
DSB will encompass nearly the entire average chromosome. An intrachromosomal joining bias is evident in the preferential joining of AID hotspots and
non-hotspots on chromosome 12 and chromosome 15 with their respective I-SceI
breaks. When a break occurs in IgH the AID target inf2 ~1 Mb from the break
appears as a robust hotspot, but when a break occurs in c-myc, inf2 is not
captured. The inverse occurs for pvt1 exon 5, an AID target on chromosome 15
that is captured by c-myc but not by IgH. We conclude that intra-chromosomal
joining is preferred to trans-chromosomal joining.
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Hi-C data shows that intra-chromosomal contact probability is inversely
proportional to distance and obeys a power law scaling with a slope of –1.08
(Lieberman-Aiden et al., 2009). We find that this closely matches the behavior of
a DSB. Rearrangement density decreases as a power function of the distance
from a break. The exponent of this power law is -1.29, close to the Hi-C estimate
of -1.08. Since rearrangement density diminishes with distance in a manner
similar to contact probability, it is mediated by proximity, a likely consequence of
local chromosome packing and nuclear chromosomal territories. We conclude
that

the

nuclear

organization

of

chromosome

territories

impacts

the

rearrangement landscape and is a determinant of rearrangement propensity.
Functionally, a strong preference for proximal intra-chromosomal rearrangement
minimizes gross genomic alterations. We propose that this may be an important
feature of DSB repair regulation that maintains genomic integrity.
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Transcription

Transcription is associated with increased rates of DNA damage and genome
instability; these effects are likely mediated by a number of different mechanisms
(Gottipati and Helleday, 2009). Transcription may expose ssDNA, which is
susceptible to chemical or oxidative damage (Aguilera, 2002). Additionally, headon collision of the replication and transcription machinery has been implicated in
fork stalling and genomic instability (Takeuchi et al., 2003). While these
phenomena have been well documented, it remains unclear which is the primary
contributor to transcription associated instability and if this is a major mechanism
of instability genome-wide.

TC-Seq data suggests that transcription associated instability plays a key role in
genome instability. First, in the case of the c-myc locus, transcription increases
the size of the local area around a DSB that is available for recombination from
50 kb to 300 kb. Rearrangements appear throughout the transcribed pvt1 gene;
this suggests that transcription is indeed recombinogenic. Perhaps more striking,
I-SceI breaks rearrange predominantly to transcribed genes genome-wide. We
find that in the absence of AID, ~50% of rearrangements occur to genes;
whereas only 40% of the genome is genic, this represents a significant
enrichment. Rearrangements also tend to occur in transcribed genes, and appear
to

increase

proportionally

with

transcription
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levels;

significantly

more

rearrangements than expected occur to highly transcribed genes while
significantly less than expected occur to silent genes. This data is further
supported by the finding that activating histone mark association and PolII
loading tends to occur on rearranged genes, but not on genes lacking
rearrangements. A bias for rearrangement between genic regions was also
reported in recent studies on tumors; in sequenced breast cancer genomes 50%
of rearrangements occur to genes (Stephens et al., 2009). However, in these
studies the role of transcription, transformation or selection in these events could
not be evaluated. Our experiments demonstrate that transcribed genic regions
are over-represented in chromosomal rearrangements in primary cells in shortterm cultures. Thus, this likely represents a general principle underlying
recombinogenesis genome-wide.

There are several non-mutually exclusive explanations for our results. They may
be a consequence of increased instability at transcribed genes, increased
recombinogenicity of transcribed genes or simple physical proximity. Composite
density analysis of the genic rearrangement profile implicates ssDNA instability
as a major contributor to transcription associated recombination. The plurality of
genic rearrangements occur to the transcription start site (TSS). The TSS is a site
of substantial KMnO4 sensitivity along the gene body, and thus the primary site of
ssDNA through the gene (Nechaev et al., 2010; Zhang and Gralla, 1989). And,
as discussed in the introduction, ssDNA has documented sensitivity to damage
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as compared to dsDNA (Frederico et al., 1990; Zhang and Gralla, 1989). Thus,
we suggest that exposed ssDNA serves as a major source of genomic instability
that predisposes transcribed genes to damage and rearrangement.

In addition to being more susceptible to damage, this effect may be due to
proximity. c-myc is transcribed in activated B cells, and, Hi-C experiments show
that transcribed regions are spatially associated in the nucleus (Lieberman-Aiden
et al., 2009). Therefore, the proximity of c-myc to other transcribed genes might
contribute to a bias for genic rearrangements. Additionally, we find that c-myc
and IgH translocate to both AID-dependent and -independent extra-chromosomal
targets at similar rates. FISH experiments in cytogenetically normal lymphoma
cell lines demonstrate that IgH and c-myc are in relatively close proximity (Roix et
al., 2003). Thus, similar rearrangement profiles of c-myc and IgH might be the
result of a shared nuclear neighborhood, the inhabitants of which are determined
by transcriptional activity.

Whatever the origin, we speculate that this

phenomenon may have

consequences for tumorigenesis. The rearrangement of proto-oncogenes to
transcribed regions may lead to their dysregulation by placing them next to
constitutively active promoters. Alternatively, rearrangements of coding regions to
one another might produce fusion proteins that alter cellular metabolism, as is the
case in CML.
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AID and Chromosome Translocation

AID initiates SHM and CSR by deaminating cytosine residues in ssDNA exposed
by transcription (Chaudhuri and Alt, 2004; Di Noia and Neuberger, 2007;
Nussenzweig and Nussenzweig, 2010; Peled et al., 2008; Stavnezer et al.,
2008). A primary site of AID activity is the IgH locus, where it generates DSBs
(Petersen et al., 2001). In addition to participating in the physiological
recombination reactions, these breaks may also partner in the generation of
chromosomal rearrangements. Indeed, in many of the mature B cell lymphomas
IgH is translocated to proto-oncogenes thereby dysregulating their expression
and driving tumorigenesis (Kuppers, 2005). Until recently, the source of breaks in
non-Ig genes translocated in mature B cell lymphomas was largely unknown. In
2008, Robbiani and colleagues demonstrated that AID generates DSBs in c-myc,
which is translocated in Burkitt’s lymphoma (Robbiani et al., 2008). They showed
one year later that AID deregulation can affect tumor growth in a mouse model of
B cell lymphomagenesis, in some cases targeting mir-142 for translocation
(Robbiani et al., 2009). Thus, the retinue of non-Ig genes conclusively shown to
suffer AID mediated DSB was 2, c-myc and mir-142.

Other studies have suggested additional DSB targets of AID. Liu and colleagues
sequenced 118 genes from germinal center B cells and showed that AID was
capable of mutating 25% of them (Liu et al., 2008). This study suggested that AID
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may act promiscuously, but it examined a very limited number of loci and only
analyzed mutations, not DSBs. Subsequent genome-wide studies examined the
locus association of certain factors by ChIP-Seq, elucidating AID’s targeting
mechanism and extending the catalog of potential AID targets. Pavri and
colleagues showed that the IgH locus and the TSSs of stalled genes load Spt5, a
PolII stalling factor (Pavri et al., 2010). AID interacts with Spt5, which associates
with thousands of loci, specifically at the TSS of stalled genes. AID ChIP-Seq
confirmed the presence of AID on genes that load Spt5 (Yamane et al., 2011).
Both the Spt5 and AID ChIP-Seq studies included mutational analysis of a few
loci in a fixed position of the gene body, but lacked a direct measurement of AID
activity genome-wide (Pavri et al., 2010; Yamane et al., 2011). Without such a
measure, these studies remain suggestive. Moreover, to date no method exists
to perform an unbiased examination of AID-mediated DSBs or translocations.
Therefore, the precise relationships between AID and Spt5 occupancy, mutation,
and translocations have not been investigated.

Here, we provide the first genome-wide direct measurement of AID activity and
the first unbiased analysis of AID-mediated DSBs. First, we show that AID targets
discrete sites for DSBs. These sites are predominantly genic; 90% of the AIDdependent rearrangement partners of IgH are in genes. We can detect
rearrangements to the transcription start sites of nearly 100 different genes that
are actively transcribed. This is consistent with many studies showing that AID is
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associated with transcription (Jung et al., 1993; Stavnezer-Nordgren and Sirlin,
1986; Yoshikawa et al., 2002), and with the positions of sequenced c-myc/IgH
translocations in primary B cells (Robbiani et al., 2008).

The TSS is a site enriched in ssDNA (Nechaev et al., 2010; Zhang and Gralla,
1989); this appears to be the primary site of AID activity genome-wide, which is
consistent with studies demonstrating AID activity on ssDNA in vitro and in vivo
(Bransteitter et al., 2003; Chaudhuri et al., 2003; Dickerson et al., 2003;
Petersen-Mahrt et al., 2002; Pham et al., 2003; Ramiro et al., 2003; Sohail et al.,
2003). While genes rearranged by AID are transcribed, expression (as measured
by mRNA-Seq) does not correlate directly with rearrangement frequency. This
suggests that transcription is necessary but not rate-limiting for rearrangement.
Rather, PolII stalling is the likely mechanism for AID targeting. This is reflected in
the distribution of AID and its co-factor Spt5 in the genome (Pavri et al., 2010;
Yamane et al., 2011), and that AID-dependent rearrangements occur mainly on
transcription start sites of stalled genes that carry high levels of the PolII stalling
factor Spt5.

Interestingly, The AID-dependent rearrangement partners of c-myc and IgH
appear largely similar. We observe a bias for intra-chromosomal joining of AID
targets to I-SceI sites. But, for extra-chromosomal AID targets, we observe no
such effect. This might be due to a shared nuclear compartment of c-myc, IgH
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and most AID-targeted genes (which are transcribed). Their mutual physical
proximity may be facilitating similar trans-chromosomal rearrangement profiles.
Given the demonstrated physical proximity of IgH and c-myc (Roix et al., 2003)
and the tendency of transcribed regions to interact (Lieberman-Aiden et al.,
2009),

transcription-associated

genomic

organization

may

mediate

this

phenomenon.

A recent study using Nbs1 ChIP-on-ChIP as a surrogate for DNA damage
suggested that AID targets repeat rich sequences (Staszewski et al., 2011).
These were proposed to occur specifically at CA repeats, non-CA tandem
repeats and SINEs. In contrast, we find no AID-dependent increase in
rearrangements to these, or any other, non-Ig repeats. This is consistent with AID
and Spt5 ChIP-Seq studies, which failed to note any loading at these sites.
Moreover, AID-dependent rearrangement hotspots predominantly occur in genes,
not in or near repeat regions that are not transcribed.

In addition, we find a strong correlation between hypermutation and
rearrangements, suggesting that genes susceptible to AID mediated DSBs are a
subset of the most highly mutated genes in the genome. Consistent with this
notion, we show that Pax5, Il21r, Gas5, Ddx6, Birc3, Ccnd2, Aff3, Grhpr, c-myc,
Pvt1, Bcl2l11, Socs1, mir142, Junb and Pim1, which are translocated or deleted
in mature B cell lymphomas, and are among the more highly mutated AID
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targets, bear AID-dependent translocation hotspots. This suggests that in
addition to hypermutation, AID is a major source of genomic instability in these
cancers. Many of the mature B cell lymphomas are thought to originate in the
germinal center, which is the primary site of AID expression and activity
(Kuppers, 2005; Muramatsu et al., 1999). And, many of the AID-initiated
translocations we describe are recurrent and clonal in these tumors. In line with
data showing that AID is oncogenic in vivo (Robbiani et al., 2009), we suggest
that AID can initiate genomic rearrangements essential for mature B cell
lymphomagenesis. It should be noted that our experiments were performed on in
vitro stimulated B cells. Germinal center B cells may have an alternate gene
expression profile that influences the number and position of AID target sites.
This may account for the absence of some genes from our hotspot lists known to
be translocated in mature B cell lymphoma. For example, we do not detect the
Bcl6/IgH translocation observed in diffuse large B cell lymphoma (Ye et al.,
1995). As such, to further extend these studies and capture the entire
complement of IgH translocation partners, we propose that TC-Seq might be
adapted for in vivo use in germinal centers.
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Future Directions

Finally, we propose that TC-Seq can be adapted for use in other cell types and
systems to study translocation biology, nuclear architecture and the mechanics of
other DNA damaging enzyme, chemicals and conditions.

Translocation profiles of other cell types. Recurrent translocations appear in
tumors other than mature B cell lymphomas. For example, most mucoepidermoid
carcinomas harbor the MECT1-MAML2 gene rearrangement and in many
prostate cancers TMPRSS2 is found fused to the ERG gene (Clark and Cooper,
2009; Hunt, 2011). In this study we have examined the rearrangement profile of
IgH, and thereby have revealed the mechanisms of its rearrangement. We
propose that examining the recombination profile of DSBs in rearrangementprone genes of other cell types might reveal the forces underlying their behavior.
TC-Seq can be performed in any cell culture, so these experiments would simply
require that the cell type of interest be isolated and grown.

Examining junctional microanatomy. TC-Seq relies on paired-end Illumina
sequencing to identify the I-SceI containing locus and a sequence displaced from
the partner sequence breakpoint; 36 nucleotides are read from each end of each
molecule. This sequencing modality has the advantage of extremely high
throughput, using latest-generation chemistry each run can yield greater than 240
million reads. Such a quantity of data allows us to assay tens of million of cells
136

concurrently while ensuring complete saturation, thereby facilitating highly
powered studies of rare events. However, Illumina paired-end sequencing does
not allow for sequencing through breakpoints. High throughput breakpoint
analysis would yield information about junctional microanatomy (deletion,
microhomology utilization and insertion) thereby allowing us to distinguish
between NHEJ and alt-NHEJ mediated events. First, one could explore the
relative contributions of these two pathways to the unselected rearrangement
landscape in primary cells. Second, these experiments could be performed in the
absence of DNA repair factors to investigate their contribution to aberrant joining
in these two pathways.

To obtain such data one needs at least 300 bp continuous sequencing reads,
through the entire fragmented DNA molecule. An alternative sequencing
technology, 454 sequencing, performs 400 bp continuous reads that would allow
such an analysis. Unfortunately, this technology is merely medium-throughput (1
million reads per run), so much less power can be achieved in these analyses.
We have successfully adapted TC-Seq for use with a 454 sequencer and are
exploring the genome-wide landscape of junctional microanatomy.

Mapping common fragile sites. Common fragile sites are areas of the genome
damaged during partial replicative stress. While about 80 of these sites are
currently known, they are generally coarsely mapped. While a sequence feature
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is likely to underlie this phenomenon the exact cause of their emergence is
incompletely defined (Durkin and Glover, 2007). These sites are documented to
partner in rearrangements (Burrow et al., 2009). We propose that TC-Seq can be
employed to map rearrangements that arise after treatment with aphidicolin, a
drug that induces DSBs at fragile sites (Glover et al., 1984). In this way, the exact
nature and location of fragile sites can be determined.

A silent gene recombinome. TC-Seq data has revealed that c-myc and IgH, both
transcribed genes, tend to rearrange to other transcribed genes. Since the
composite density analysis of genic rearrangements reveals a bias to the
transcription start site, ssDNA fragility may be a partial determinant of this bias.
However, what role genomic architecture plays in this trend is unknown. We
propose that obtaining the recombinome for a DSB in a silent gene could reveal
the relative roles of ssDNA instability and spatial proximity in this phenomenon.
We expect that if differential localization of transcribed and non-transcribed
genes impacts rearrangement profiles, a DSB in a silent gene should recombine
less frequently than a DSB in an active gene to other transcribed genes. Such an
experiment could be performed by generating a knockout mouse with an I-SceI
site in a gene silent in B cells, or by performing TC-Seq on IgH in a cell type in
which it is unexpressed.
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Exploring RAG-induced non-Ig DSBs. RAGs may catalyze non-Ig DSBs. These
DSBs may participate in rearrangement observed in B cell lymphomas
(Vaandrager et al., 2000). However, the spectrum of RAG targeting is unknown.
TC-Seq may be adapted to discover these targets. We propose that pre-B cells
bearing I-SceI sites may be isolated from mouse bone marrow and infected with
Ablson virus, thereby immortalizing and freezing them in an early large pre-B cell
stage in which RAGs are not expressed (Muljo and Schlissel, 2003).
Administration with STI-571 (Gleevec) will allow cells to differentiate into the late
pre-B cell stage and enforce RAG expression (Muljo and Schlissel, 2003). At this
time cells can be infected with I-SceI to generate RAG-mediated rearrangements
to that site.

RAG function differs substantially from AID. While AID has no known end
protection function, RAG2 shepherds DSBs to faithful joining by the NHEJ
pathway (Corneo et al., 2007). Thereby, RAG-generated ends may be less
amenable to rearrangement generation than AID generated ends. coreRAG2
released DNA ends may be more available to aberrant joining (Corneo et al.,
2007; Deriano et al., 2011); we propose that using this RAG2 mutant in TC-Seq
might facilitate non-Ig RAG target discovery.
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CHAPTER 7:
Methods

B Cell Cultures, Infections and Sorting

Resting B lymphocytes were isolated from mouse spleens by immunomagnetic
depletion with anti-CD43 MicroBeads (Miltenyi Biotech) and cultured at 0.5 × 106
cells/ml

in

RPMI

supplemented

with

L-glutamine,

sodium

pyruvate,

antibiotic/antimycotic, HEPES, 50 μM 2-mercaptoethanol (all from GIBCO-BRL),
and 10% fetal calf serum (Hyclone). B cells were stimulated in the presence of
500ng/ml RP105 (BD Pharmingen), 25 μg/ml lipopolysaccharide (LPS) (Sigma)
and 5 ng/ml mouse recombinant IL-4 (Sigma). Retroviral supernatants were
prepared by cotransfection of BOSC23 cells with pCL-Eco and pMX-IRES-GFPderived plasmids encoding for I-SceI-mCherry or AID-GFP with Fugene 6, 72 hr
before infection. At 20 and 44 hr of lymphocyte culture, retroviral supernatants
were added, and B cells were spinoculated at 1150 g for 1.5 hr in the presence of
10 μg/ml polybrene. For dual infection, separately prepared retroviral
supernatants were added simultaneously on both days. After 4 hr at 37°C,
supernatants were replaced with LPS and IL-4 in supplemented RPMI. At 96 hr
from the beginning of their culture, singly infected B cells were collected and
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frozen in 10 million cell pellets at -80C. Dually infected B cells were sorted for
double positive cells with a FACSAria instrument (Becton Dickson) then frozen
down.
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Translocation Capture Sequencing (TC-Seq)

Genomic DNA Extraction and Sonication

5x10 million B cell aliquots were thawed on ice. Cells were resuspended in 100ul
of Phosphate buffered saline (PBS) and transferred to a 15ml conical tube
containing 5mL Proteinase K buffer (100mM Tris pH8, 0.2% SDS, 200mM NaCl,
5mM EDTA) and 50ul of 20mg/ml Proteinase K. Cells were digested overnight at
55C. To extract DNA, addition of 5mL of phenol-chloroform was followed by 30s
of gentle inversion and 20 minutes of centrifugation at 4000rpm. The aqueous
phase was transferred to a 50ml conical tube containing 12.5mL of 100%
ethanol. The mixture was centrifuged for 15 minutes at 4000rpm at 4C. The pellet
was washed twice with 5mL 70% ethanol, transferred to a microcentrifuge tube,
air dried for 5 minutes and resuspended in 100uL 10mM Tris pH8 with 1uL of
0.5mg/ml DNAse-free RNAse (Roche). Genomic DNA concentration was
adjusted to 167ng/uL with 10mM Tris pH8 and divided into microcentrifuge tubes
containing 300uL each. Genomic DNA was fragmented by sonication at low
power for 7 cycles (30” on/30” off) in a Bioruptor (Diagenode) to yield a 5001350bp distribution of DNA fragments. DNA was further divided into 50x30ul
(5ug) aliquots in 1.5mL eppendorf tubes.
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Genomic DNA Fragment Preparation, Linker Ligation and Elimination of
Unrearranged Loci

Each experiment consisted of genomic DNA from 50 million B cells in 50 x 5ug
aliquots for a total of 250ug of fragmented genomic DNA. The following reactions
were performed individually on 5ug aliquots. DNA was blunted by End-It DNA
Repair Kit (Epicentre) then purified by Qiagen PCR purification column and
eluted in 43uL of Buffer EB. Blunted DNA was adenosine-tailed by addition of 5ul
10x NEB2 buffer, 1uL 10mM dATP and 2uL Klenow fragment 3->5’ exo- (NEB)
followed by incubation at 37C for 1hr. Each reaction was purified by Qiagen PCR
purification kit and eluted in 40uL of Buffer EB. Each aliquot of blunted, A-tailed
DNA fragments was ligated to 200pmol of linkers by addition of 4uL linker, 5uL
NEB T4 DNA ligase buffer and 1uL high concentration T4 DNA ligase (NEB)
followed by incubation overnight at 16C. Ligase was inactivated by incubation at
70C for 20 minutes, reactions were purified by Qiagen PCR purification column
and eluted in 44uL Buffer EB. Native loci were eliminated by adding 5uL 10x NEB
Isce1 buffer, 0.5uL 100x BSA and 1uL I-Sce1 then incubating the reaction at 37C
for 2 hours. Each reaction was purified by Qiagen PCR purification column and
eluted in 50uL Buffer EB. Finally, all 50 reactions were pooled.
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PCR Round 1

Pooled linker-ligated DNA was divided into 2 equal parts for semi-nested ligationmediated PCR using either forward or reverse primers. Forward and reverse
enrichment streams are kept separate for the entire remainder of the protocol.
DNA was divided into 1ug aliquots and mixed with 20ul 5x Phusion HF buffer, 3ul
10mM dNTPs, 1ul 20uM biotinylated pMycF1, pMycR1, pIgHF1 or pIgHR1, 1uL
of Phusion Taq (Finnzymes) and H2O to 100uL. Single-primer PCR reactions
were run – 1x(98C-1min) 12x(98C-15sec, 65C-30sec, 72C-45sec) 1x(72C-1min)
1x(4C-forever) - then each tube was spiked with 1ul 20uM pLinker and subjected
to additional cycles of PCR - 1x(98C-1min) 35x(98C-15sec, 65C-30sec, 72C45sec) 1x(72C-5min) 1x(4C-forever). Forward and reverse PCR reactions were
pooled separately, and 400uL of each was purified in 4 Qiagen PCR purification
columns, each eluted in 50uL EB. All 200ul of each sample was run on a 2%
agarose gel until well separated and appropriately size fragments [for IgHI: F
(350bp-1kb) R (300-1kb), for MycI: F (300bp-1kb) R (300-1kb)] were excised.
DNA was purified in Qiagen Gel purification columns and gel-based size
selection was repeated once. 100uL of washed magnetic T1 magenetic
streptavidin beads (Invitrogen) were resuspended in 400ul 2x B&W buffer (10mM
Tris pH7.5, 1mM EDTA, 2M NaCl), 200ul was added to each forward and reverse
PCR1 products and the mixture incubated for 1hr with gentle nutation at room
temperature. Beads were isolated, washed 3x in 500uL 1x B&W buffer, 1x in
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ddH2O and resuspended in 87ul H2O. Unrearranged loci were further eliminated
by adding 10ul 10x NEB Isce1 buffer, 1ul 100x BSA and 2uL Isce1, then
digesting DNA on beads for 2 hours at 37C. Beads were washed 3 times in 1x
B&W, once in H2O and resuspended in 50uL H2O.

Round 2 PCR

20ul of beads from each of the forward and reverse PCR1 was separately mixed
with 40ul 5x Phusion HF buffer, 6ul 10mM dNTPs, 2ul 20uM pIgHF2, pIgHR2,
pMycF2 or pMycR2, 2uL 20uM pLinker, 2ul Phusion taq and 128ul H2O then
separated into 50ul aliquots and subjected to PCR - 1x(98C-1min) 35x(98C10sec, 65C-30sec, 72C-40sec) 1x(72C-5min) 1x(4C-forever). PCR reactions
were separated from beads and each tube was run on one lane of a 2% agarose
gel until appropriate separation was achieved. Desired fragment sizes were
excised [for IgHI: F (300bp-1kb) R (250-1kb), for MycI: F (270bp-1kb) R (2701kb)] and purified by Qiagen gel purification column. Size selection was repeated
once more in 4 Qiagen gel purification columns for each forward and reverse;
each column was eluted with 30uL EB.

Preparing Enriched DNA for Paired-end High Throughput Sequencing

120ul of isolated DNA was mixed with 13uL 10x NEB Buffer 4, 2uL of Asc1 and
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H2O to 150ul then incubated at 37C for 2 hours to cleave the linker off enriched
products. Restriction digests were purified by Qiagen PCR purification column
and redigested with Asc1 to ensure complete linker removal. Desired fragment
sizes [for IgHI: F (250bp-1kb) R (200-1kb). for MycI: F (220bp-1kb) R (220-1kb)]
were isolated by eletrophoresis on a 2% agarose gel and isolated by Qiagen gel
purification column. DNA was blunted by End-It DNA Repair Kit (Epicentre),
column purified, A-tailed as described above and ligated to Illumina paired end
adapters. Ligation reactions were column purified then run on a 2% agarose gel
and desired fragment sizes isolated [for IgHI: F (320bp-1kb) R (270-1kb), for
MycI: F (300bp-1kb) R (300-1kb)] (Note, at this point the product may not be
visible on the gel). Adapter ligated fragments were enriched by 25 cycles of PCR
with Illumina PCR primers PE1.0 and PE2.0 and desired fragment sizes isolated
on a 2% agarose gel [for IgHI: F (400bp-1kb) R (350-1kb), for MycI: F (380bp1kb) R (380-1kb)]. Samples were confirmed to be enriched for rearranged loci by
TOPO cloning and screening 10 forward- and 10 reverse-enrichment colonies.
Finally, appropriate size distribution was confirmed by Agilent Bioanalyzer.
Forward and reverse libraries for the same sample were mixed in equimolar
ratios and sequenced by 36x36 or 54x54 paired-end deep sequencing on an
Illumina GAII.
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Mapping of Translocation Hotspots

A translocation hotspot was defined as a localized enrichment of translocation
events above what is expected from the null hypothesis of uniform distribution of
translocation events along the genome. To identify such hotspots, candidate
regions were defined as locations containing consecutive translocations with
distances shorter than expected from the mappable size of the mm9 genome
assembly (P < 0.01 each as determined by a negative binomial test). For a
candidate region to be called a hotspot it had to (1) have more than 3
translocations and (2) have at least one read from each of the two sides of the
bait and (3) have at least 10% of the translocations come from each side of the
bait and (4) have a combined P value less than 10-9 given the number of
translocations and length of the region as determined by a negative binomial test.
Hotspots with a large degree (>80%) of overlap with repeat regions or small
footprints (<100nt) were removed. For AID-dependent hotspot lists hotspots with
less than 10-fold enrichment over the AID-/- control were removed. Analyses of
RNA-Seq, chromatin modifications, AID-, PolII-, and Spt5-ChIP as well as the
identification of cryptic I-SceI sites, TSSs, genic and intergenic domains were
carried out in R (http://www.R-project.org).
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Hypermutation Analysis

CD43- splenocytes from IgkAID-Ung-/- or Aicda-/- mice were cultured at 0.1 x 106
cells/ml with LPS+IL-4, and 0.5 mg/ml of aCD180 (RP105) antibody (RP/14, BD
Pharmingen). At 72 hrs cells were diluted 1:4 and cultured for another 48 hs. 50
ng of genomic DNA was amplified for 30 cycles with Phusion DNA polymerase
(New England Biolabs) and specific primers. For nested PCR, two-20 cycle
amplifications were performed with DMSO. The amplicon was cloned using PCR
Zero blunt (Invitrogen) and sequenced.
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Primers

50mM double stranded asymmetric linker (dsaLinker) was generated by mixing
equimolar parts of pLT and pLB in annealing buffer (10 mM Tris, pH 8.0, 50 mM
NaCl, 1 mM EDTA), heating the mixture to boiling, then incubating it at room
temperature for 2 hours.

Table 7.1. Primers for TC-Seq.
Name

5' modification

pLT
pLB

Phosphorylated

pLinker
pMycF1

Biotinylated

pMycR1 Biotinylated
pIgHF1

Biotinylated

pIgHR1

Biotinylated

pMycF2
pMycR2
pIgHF2
pIgHR2

Sequence
GCAGCGGATAACAATTTCAC
ACAGGACGTACTGTGGCGC
GCCT
GGCGCGCCACAGTACTTGA
CTGAGCTTTA
GCAGCGGATAACAATTTCAC
ACAGGAC
CAAAATTGGGACAGGG
ATGTGACC
GGTGTCAAATAATAAGAGAC
ACCTCCC
GCTTATTGTTGAATGGGCCA
AAGGTC
CTAAAGCAATGACTGAAGAC
TCAGTCCC
CTTGGGGGAAACCAGAGGG
AATC
TACACTCTAAACCGCGACGC
C
GGTAGGCCTGGACTTTGGG
TC
ACTGTGGCTGCCTCTGGCTT
AC
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3' modification

dideoxycytosine

Table 7.2. Primers for hypermutation analysis. (Pages 150-151)

Gene

Nfkb1

mir21

mir-155

Primer_F

Primer_R

CTCTCCG
CACCACG
GTGCAG
CTTTTAAA
TAAAGCAA
GGCTTTTA
CCACAG
CAAAGCT
GACAGGA
AAGTCCA
G

GAGGTCAG
GCACAAAA
CATG
62c
CATGGAGTT
AATAATAGA
CAGGACAA
AG
60c

ACTGTCCT
GCAGGCC
Csk
ACTGAT
TGAACTCC
TGACCTTC
Apobec3 AGAAG

Clec2d

Ikzf1

bcl11a

Gpr15

Blr1
Spib

Anne
aling
Temp

CTTCCCTA
CCTATGCT
TAGTC
CATTCTTG
GCCCCCA
AAGC
ATGTGAA
CCGAGCC
GTCGT
AATCCAG
CCAACCA
GACAAC
CTGGTCC
TGCTTGG
AACTTTA
GCTCTGT

CAGCTGAC
CCCACTCT
GC

Anne
Nested_
aling
Primer_R temp
GAGGTC
AGGCAC
AAAACA
TG
64c

64c

CAGATGGC
CCACACGA
TTAG
60c
TGTTCTACC
TCCAAGTCC
TAC
60c
TCAAGAGCT
CAAAACAGA
AAGG
CCCTAACAC
CAGTTTGGT
TCTG
GGGGTGAG
GGTGCGAA
CTAAT
ACTGGACT
GCTGTGCT
GTTC
ACGTCTGG
CCTCATGCT
TTC
TGAGGCCA

Nested_
Primer_F
GAAGC
GGAGA
GGAACT
CTTG

60c

60c

60c

60c

60c
60c
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GAGAG
CAGAGA GAAGTC
GGTGA
TTATAA
GTGCTG GCAATG
G
C

60c

AGGAG
GTAGAA
GTGGGT
AAG

60c

AAAGGA
TTTGGT
CCTGAG
TAG

aicda
Repeat1
(chr19)
Repeat2
(chr11)
Repeat3
(chr2)

Serinc3

mir715

CTTCCTAG
ACAAG
CCCTTGA
GTCTGGTT
TGCATTG
TTGTCCAG
ATGAACTT
GACTGTG
GTCTGTA
GATGTAG
CTCTCTTC
CTGGCTAT
GTCCCAG
TTCTTC
ATACCTTT
TAGAGGA
GGCTGTA
C
CCTAGGT
GCCTGCT
TCTGAG

GAAGTAGAT
GATC
GAGGCAGG
TGGATCATT
CTG
TGGTTTTCA
TTTTCGGTG
TCTTCTG
GTATTCCAC
CAAGATCTG
CTTAG
CATGTGCA
GGAACATG
TAACTAAG

60c

60c

60c

62c

GTAACTCAG
GTGATTAG
GTCTTG
60c
AGGGAACG
ACACAGCA
GAAC
60c
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